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ABSTRACT OF THESIS 
 
Involvement of the Sigma-1 Receptor in Methamphetamine Mediated Changes to 
Astrocyte Structure and Function 
 Methamphetamine is a highly addictive psychostimulant drug. There are currently 
no FDA-approved pharmacological treatments for methamphetamine addiction. 
Pharmacologically, (+)-methamphetamine is a dopamine releasing agent and dopamine 
transporter substrate that redistributes dopamine from intracellular vesicles via the 
vesicular monoamine transporter 2 (VMAT2) and reverses the direction of dopamine 
transport in the dopamine transporter. Methamphetamine, cocaine, and other drugs of 
abuse are also sigma-1 receptor ligands, and previous studies have demonstrated the role 
of the sigma-1 receptor in modulating the behavioral and cellular effects of these drugs. 
However, almost all these studies were conducted in cell culture systems or with emphasis 
on the neuronal effects of sigma-1 receptor binding.  
 In the literature, the sigma-1 receptor localizes robustly within neurons throughout 
the brain. However, there are conflicting results regarding localization in astrocytes. Here, 
immunohistochemical experiments were conducted on rat brain tissue containing either the 
nucleus accumbens or the prelimbic cortex, two brain regions critical in mediating drug-
seeking behavior, in order to confirm expression of the sigma-1 receptor in astrocytes. It 
was determined that the sigma-1 receptor is ubiquitously expressed among neurons and 
modestly expressed among glial fibrillary acidic protein (GFAP)-positive astrocytes. There 
were no noted statistically significant differences between the proportion of cell types 
expressing the sigma-1 receptor in the prelimbic cortex and the nucleus accumbens. Next, 
the effect of methamphetamine and the role of the sigma-1 receptor on astrocytic 
morphology and sigma-1 receptor distribution were probed by incubating slices of striatal 
tissue in methamphetamine solution with or without the sigma-1 receptor antagonist BD-
1063 and the sigma-1 receptor agonist PRE-084. Only the methamphetamine-treated slice 
exhibited a significantly different amount of stellations than the other slices. The sigma-1 
receptor antagonist BD-1063 and PRE-084 abolished the redistribution of sigma-1 receptor 
to the processes of the astrocytes induced by methamphetamine. Thus, the data confirms 
that astrocytes in both the prelimbic cortex and nucleus accumbens express the sigma-1 
receptor. Moreover, methamphetamine induces statistically significant redistribution of the 
sigma-1 receptor that is abolished by BD-1063 and PRE-084. 
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CHAPTER 1. MECHANISMS OF METHAMPHETAMINE ACTION 
1.1 Methamphetamine as Drug of Abuse 
 
 The consequences of methamphetamine abuse place significant burden on the 
economy of the United States. According to a 2009 report, methamphetamine abuse 
cost an estimated $23.4 billion to citizens of the United States (Nicosia et al., 2009). 
Results from the United State National Survey on Drug Use in 2016 suggest that a 
significant proportion (1.6 million) of the population had used methamphetamine in the 
past year (SAMHSA, 2017). Moreover, methamphetamine addiction is difficult to treat 
due to high rates of relapse. It was estimated in a sample of patients admitted 
specifically for methamphetamine abuse that 61% relapsed within a year after 
discharge and an additional 25% during years 2-5 following discharge (Brecht and 
Herbeck, 2014). Additionally, methamphetamine use is increasing in the United States 
according to recent estimates (Jones et al., 2020). There are currently no FDA-approved 
pharmacological therapies for the treatment of psychostimulant abuse, highlighting the 
urgent need for research into the mechanisms by which psychostimulant dependence 
and addiction develop. Three drugs in the class of substances known as 
psychostimulants are cocaine, amphetamine (AMP), and methamphetamine (METH). 
All three drugs elevate dopamine concentrations in the ventral striatum, contributing to 
their reinforcing effects, yet they do so by distinct mechanisms, with AMP and METH 
sharing similar mechanisms of extracellular dopamine elevation. The following is a 
discussion of these mechanisms. 
 
1.2 Mechanism of AMP/METH-Mediated DA Release 
 
1.2.1  Actions at DAT 
Among the psychostimulants, there are two general mechanisms of action. 
Drugs can either promote the release of dopamine into the synaptic cleft or they can 
 
2 
 
block the reuptake of dopamine into the presynaptic neuron. Both of these 
mechanisms require the dopamine transporter. The crystal structure for a 
humanized Drosophila melanogaster dopamine transporter in complex with several 
ligands has been solved. Both methamphetamine and amphetamine bind in a site 
very close to that of dopamine. The basic amine group on both molecules interacts 
with an aspartate residue (D46), as does the basic amine group on dopamine. Both 
d-amphetamine and d-methamphetamine form a hydrogen bond with the carbonyl 
group on the phenylalanine residue F319. That amphetamine, methamphetamine, 
and dopamine share very similar poses in the binding site (allowing for interaction 
with the transporter subsite) suggests that it is plausible that amphetamine and 
methamphetamine act as substrates for the dopamine transporter rather than simple 
inhibitors (Wang et al., 2015). Cocaine, on the other hand, does not allow for this 
interaction and can therefore be considered a pure inhibitor of the dopamine 
transporter (DAT). Indeed, cocaine is a classical dopamine reuptake inhibitor that 
stabilizes the outward-facing conformation of the dopamine transporter by binding 
to a site near that of dopamine in models of the dopamine transporter based on the 
structure of the bacterial leucine transporter (LeuT; Beuming et al., 2008). 
Experiments examining the uptake of radiolabeled amphetamine into rat 
brain synaptosomes demonstrate that a variety of reuptake inhibitors, including 
methamphetamine, can inhibit the transport of amphetamine into synaptosomes, 
suggesting that amphetamine acts as a substrate, rather than an inhibitor of 
dopamine uptake (Zaczek et al., 1991) at the concentrations assayed (5 nM). The 
dopamine transporter is electrogenic, and transport is coupled with influx of 2 Na+ 
ions and 1 Cl- ion. This amphetamine uptake was oubain-sensitive (oubain inhibits 
the Na+/K+ ATPase), an effect that can be linked to the requirement of inward 
sodium flux by the Na+/K+-ATPase is required to maintain the concentration 
gradient of Na+ and K+. Experiments in Xenopus oocytes transfected with DAT 
revealed that cocaine can block the inward current generated by DAT. 
Amphetamine, on the other hand, generates an inward current, suggesting that it 
 
3 
 
drives cation transport into the cell, and the I-V plots for classical uptake inhibitors 
and releasing agents are distinct (Sonders et al., 1997). 
Further evidence that cocaine and amphetamine/methamphetamine differ in 
their action at the dopamine transporter resulted from early work that demonstrated 
that cocaine can block the increase in blood pressure induced by tyramine, an amine 
that also releases catecholamines like amphetamine and methamphetamine, yet 
both drugs alone elevate blood pressure (Tainter and Chang, 1927). This finding 
was corroborated by studies in which other pure dopamine reuptake inhibitors such 
as benzotropine and methylphenidate could inhibit the efflux of labeled dopamine 
induced by amphetamine in the rat corpus striatum and in HEK293 cells expressing 
the dopamine transporter, respectively (Liang and Rutledge, 1982; Simmler et al., 
2013). This suggests that DAT is necessary for the dopamine-releasing properties 
of amphetamine. 
Evidence for the fact that there is more to amphetamine-mediated dopamine release 
than simple reuptake inhibition comes from a study that suggests that the affinity 
at the dopamine transporter cannot explain the behavioral potency of amphetamine 
(Ritz et al., 1987). In this case, behavioral potency was measured in primates. 
Essentially, monkeys were trained to self-administer a standard dose cocaine. 
Subsequently the solution was switched to contain varying concentrations of the 
test drug. The rate of responding to the test drug was utilized as the metric to 
calculate behavioral potency. The behavioral potency of (+)-amphetamine cited in 
this study was 0.20, similar to the drug mazindol, yet the binding affinity of 
mazindol is some 156 times greater than the affinity of (+)-amphetamine for DAT.  
Inward transport of AMP as a substrate at DAT is critical for its dopamine-
releasing actions. However, as amphetamine and methamphetamine are both 
lipophilic weak bases (meaning they can pass through the plasma membrane), it is 
plausible that these compounds do not require transport via DAT at higher 
concentrations, but rather can cross the plasma membrane by passive diffusion 
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(Mack and Bönisch, 1979). Moreover, the dopamine transporter does not merely 
act to transport amphetamine or methamphetamine into the cell; indeed, the 
dopamine transporter is critical for the release of dopamine observed during 
amphetamine treatment (Kahlig et al., 2005; Pifl et al., 1995). However, actions at 
the dopamine transporter cannot explain the entire picture of how AMP mediates 
release of dopamine. For example, if DAT alone mediates the effects AMP and its 
affinity for DAT is so low, then why is AMP so potent at eliciting stimulant effects? 
Why does a smaller dose of methamphetamine elevate extracellular dopamine in 
the nucleus accumbens to similar levels or even greater levels as a larger dose of 
cocaine (Zhang et al., 2001; Nakagawa et al., 2011), despite its markedly decreased 
affinity at DAT (Ritz et al., 1987)? 
1.2.2 Vesicular Actions of AMP/METH 
In dopaminergic neurons, synaptic vesicles are loaded with dopamine 
primarily by the protein VMAT2. The other vesicular monoamine transporter, 
VMAT1, is localized primarily in adrenal chromaffin cells and other peripheral cell 
types (Schuldiner et al., 1995). The operation of VMAT is driven by a proton 
gradient (high concentration of protons in the vesicle, lower concentration in the 
cytosol) that is generated by a vacuolar H+-ATPase. Indeed, amphetamine collapses 
the pH gradient maintained by the vacuolar H+-ATPase, particularly at high 
concentrations. However, at low concentrations the loss of the pH gradient cannot 
account for dopamine released from rat brain synaptic vesicles (Floor and Meng, 
1996).  VMAT then transports monoamines into the vesicle by transporting protons 
out of the vesicle; two protons are exchanged for a positively charged monoamine 
substrate. Given that this process is proton driven, it is plausible that certain weak 
bases might diffuse through the vesicle membrane and disrupt the proton gradient. 
Indeed, this is the case seen when adrenal chromaffin cells are treated with the weak 
base chloroquine, and a similar effect is observed when the vacuolar H+-ATPase is 
inhibited with bafilomycin (Pothos et al., 2002). Both AMP and METH are also 
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weak bases and both induce redistribution of dopamine from vesicles. Thus, the 
weak base hypothesis of amphetamine/methamphetamine action was proposed. 
The situation is not as simple as passive diffusion of amphetamine into 
synaptic vesicles and subsequent alkalinization of those vesicles; there appears to 
be stereoselectivity in terms of which isomer of methamphetamine inhibits VMAT2 
more, with the (+)-isomer having greater potency (Peter et al., 1994). These 
findings are recapitulated in an experiment in VMAT-expressing HEK cells treated 
with a fluorescent substrate for VMAT; both S-(+)-amphetamine and S-(+)-
methamphetamine inhibited uptake of this fluorescent substrate more than R-(-) 
isomers. Simple inhibition of VMAT2 cannot explain the dopamine releasing 
effects of AMP or METH since reserpine, an inhibitor of VMAT2, actually depletes 
the presynaptic terminal of dopamine, presumably by allowing dopamine to 
accumulate in the cytosol where it is vulnerable to metabolism by monoamine 
oxidase enzymes. Rather, there is evidence that amphetamine acts as a substrate for 
VMAT that is transported into the vesicle by proton antiport and alkalinizes the 
interior of synaptic vesicles. The fluorescent substrate, FFN206, was used to label 
vesicles in the Drosophila melanogaster brain revealing labeling of nerve terminals 
throughout the D. melanogaster brain. The animals were transfected with dVMAT-
pHluorin, a fluorescent, pH-sensitive molecule inserted into the dVMAT protein. 
This allowed for simultaneous pH data and VMAT transport activity data to be 
recorded. Amphetamine dose-dependently increased the pH within vesicles, 
confirming the hypothesis that it acts as a weak base. This alkalinization was 
blocked for both amphetamine and methamphetamine when dDAT (Drosophila 
dopamine transporter) was knocked out, highlighting the fact that both AMP and 
METH are substrates for DAT. To determine whether the alkalinization of the 
vesicle was primarily a function of the weak base properties of AMP and METH, a 
substrate that could not be protonated (MPP+) was assayed. It was found that MPP+ 
could also alkalinize vesicles albeit with lower potency than AMP or METH. This 
suggests that the H+ antiport mediated by substrate uptake is sufficient to alkalinize 
the vesicle (Freyberg et al., 2016). Thus, pure weak bases like chloroquine, which 
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lacks any affinity for VMAT2, displace monoamines from vesicles by a 
fundamentally different mechanism than amphetamine or methamphetamine; the 
unmodified weak-base hypothesis is not sufficient to account for the dopamine 
released by AMP or METH. Rather, AMP and METH are substrates for VMAT, 
and the substrate-coupled proton antiport action of these compounds is critical for 
alkalinization of the vesicle and subsequent displacement of dopamine (Hiranita 
and Freyberg, 2016). The only difference between this hypothesis and the general 
weak base hypothesis is that METH and AMP are also VMAT2 substrates whereas 
chloroquine is purely a weak base. This modified hypothesis does not preclude the 
possibility that AMP and METH can traverse the membrane of vesicles, but rather, 
it states that the primary mechanism by which AMP and METH enter the vesicle is 
by inward transport via VMAT2. 
1.2.3 Hypotheses of AMP/METH-Mediated DA Release 
The net effect of AMP/METH administration, that is, the release of DA 
from the presynaptic nerve terminal, cannot be explained by the actions of these 
compounds at VMAT, nor can simple inward transport mediated by DAT explain 
the observation that AMP and METH promote dopamine release. Moreover, 
dopamine is a substrate for the monoamine oxidase enzymes which are localized in 
the cytosol and in mitochondria – this means that any dopamine displaced from 
vesicles must rapidly exit the presynaptic terminal of the dopaminergic neuron, or 
it is vulnerable to degradation by monoamine oxidase enzymes (see 1.2.4 for 
AMP/METH interaction with MAO enzymes).  
This is the basis of the facilitated exchange diffusion model of amphetamine 
action (Figure 1.1) which proposes that dopamine transporters bind intracellular 
dopamine due to the overwhelmingly high cytosolic concentration of dopamine in 
the presence of METH/AMP (due to displacement of dopamine from vesicles to 
the cytosol) and then release it to the extracellular milieu. The inward-facing 
conformation of the DAT would be transient due to low intracellular sodium 
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concentrations, but AMP, which both promotes the inward-facing conformation 
and increases intracellular dopamine would facilitate greater release of dopamine 
via DAT. This model is known as the facilitated exchange diffusion model and was 
initially used to describe reverse transport by the glucose transporter (Stein, 1967). 
As described above, a key facet of this model is that extracellular sodium 
concentrations are high. The presence of the sodium ion stabilizes the conformation 
of the dopamine transporter such that it is normally locked in its outward, 
extracellular-facing conformation (i.e. in the absence of substrate). When 
amphetamine binds to DAT, it induces a conformational change and is released into 
the cytosol, alongside the sodium and chloride ions. Since intracellular sodium 
concentrations are much lower than the extracellular concentration, the inward open 
conformation of DAT is transient, but if intracellular dopamine concentrations were 
high enough, the dopamine could bind to the inward open conformation and be 
transported out of the cell. The involvement of sodium in stabilizing the 
conformation of monoamine transporters was initially proposed by Bogdanski and 
Brodie in 1969 (Bogdanski and Brodie, 1969). In those experiments, it was found 
in rat heart tissue slices that media not containing sodium (i.e. intracellular sodium 
concentration is higher than extracellular sodium concentration) favored release of 
norepinephrine while sodium-rich media favored uptake of norepinephrine (more 
[3H]norepinephrine remained in the tissue in sodium-rich conditions than in 
sodium-poor conditions). Additionally, it was also found that potassium plays a role 
in the net inward flux of norepinephrine, as K+ has an antagonistic effect on 
norepinephrine transport into the cell. The authors hypothesized that K+ competes 
for the same binding site as Na+. When the transporter faces inwards, the Na+ 
binding site is exposed to the cytosol where K+ concentrations are high. In the 
presence of high K+, the transporter releases both the norepinephrine and the Na+ 
ion. 
The work of Fischer and Cho provided critical evidence for the facilitated 
exchange diffusion model of amphetamine action (Fischer and Cho, 1979). First, it 
was demonstrated that the release of [3H]dopamine by d-AMP was temperature-
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dependent, suggesting that active transport is required for dopamine release. 
Second, it was demonstrated that dopamine release is partially saturable, suggesting 
that a population of a particular protein mediating (DAT) dopamine release by d-
AMP. Third, the observed release was blocked by cocaine, recapitulating work 
suggesting that AMP requires the dopamine transporter for its function. Fourth, 
decreasing extracellular sodium concentrations shifted the dose-response curve of 
dopamine released vs. concentration of AMP to the right, meaning sodium plays a 
role in dopamine release by DAT. The latter finding supports the hypothesis that 
the sodium ion plays a role in the uptake of substrate by stabilizing the open 
conformation of DAT. It is important to note that increasing the concentration of 
intracellular sodium also facilitates efflux both in the absence and presence of AMP 
(Khoshbouei et al., 2003). That simply increasing intracellular sodium can increase 
efflux contradicts the facilitated exchange diffusion hypothesis because this 
suggests that there is no requirement for inward transport in order to promote efflux. 
Experiments utilizing the Drosophila melanogaster dopamine transporter (dDAT) 
co-crystallized with Na+ suggest that Na+ alone promotes a transition from the apo 
(completely unbound state) state to the outward open state in which the substrate 
binding site is exposed. Binding of Na+ also stabilized the inner gate of dDAT and 
destabilized regions involved in promoting the outward open configuration of 
DAT. When dopamine is bound to the Na+-bound dDAT, dDAT favors an outward 
closed conformation. This suggests that dopamine and sodium binding are 
prerequisites for transition to the closed conformation (Nielsen et al., 2019). The 
results from Khoshbouei and coworkers suggest that these properties are retained 
in the inward-facing conformation. Importantly, because the concentration of Na+ 
is lower intracellularly than extracellularly, the stabilized, inward open 
conformation is transient. However, due to elevated intracellular dopamine, the 
likelihood of dopamine binding to the inward-facing open conformation is 
increased despite the lower Na+ concentration in the cytosol. 
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Figure 1.1 The facilitated exchange diffusion model. The red circles represent the sodium 
ion, the green triangles, amphetamine, and the purple triangles, dopamine. Binding of 
sodium to the unbound state of DAT (Apo-DAT) induces a conformational change that 
allows dopamine or amphetamine to bind to its binding site on the dopamine transporter. 
A series of conformational changes occur in the structure of DAT which results in inward 
transport of dopamine. The inward-facing conformation of DAT binds intracellular 
sodium and dopamine. In this model the elevated intracellular concentration of dopamine 
mediated by AMP actions permits dopamine binding to the inward-facing, sodium-bound 
conformation of DAT. Once dopamine binds, DAT undergoes a conformational change, 
releasing dopamine to the extracellular space. 
Dopamine efflux mediated by injection of dopamine into the giant 
dopaminergic neuron of Planorbis corneus (pond snail) can be blocked by 
dopamine transporter inhibitors such as nomifensine, suggesting that the dopamine 
transporter mediates both efflux of dopamine from the neuron and also influx of 
dopamine into the neuron. This suggests that increased intracellular concentration 
of dopamine, perhaps that induced by dopamine redistribution from vesicles due to 
the action of AMP on VMAT, is sufficient to promote release of dopamine through 
the dopamine transporter. In other words, despite lower intracellular Na+ 
concentration, an elevated concentration of intracellular dopamine is sufficient to 
promote binding to the inward-facing conformations of DAT. In the same study, 
amphetamine was injected directly into the giant dopaminergic neuron, and this 
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dramatically increased the concentration of cytosolic dopamine. Moreover, as 
expected, amphetamine decreased the quantal size in PC12 cells, measured by 
evoking release with KCl (Sulzer et al., 1995). The facilitated exchange diffusion 
model assumes that AMP binds to DAT and induces an inward-facing conformation 
due to inward transport. Because dopamine release occurred even when 
amphetamine was directly injected into the cell, the facilitated exchange diffusion 
model cannot explain dopamine release in these experiments. 
Other hypotheses have emerged to explain dopamine efflux mediated by 
AMP. The advent of rapid patch clamp technology has enabled researchers to 
observe very rapid, large events that are not stoichiometrically associated with 
substrate translocation (i.e. the magnitude of the charge movement exceeds that 
associated with substrate transport). This uncoupled ion conductance has been 
observed for monoamine transporters such as SERT (Mager et al., 1994) and DAT 
(Sonders et al., 1997). The existence of these uncoupled currents suggests a 
channel-like mode of conductance in DAT. It has been suggested, based on outside-
out patch clamp experiments in HEK293 cells stably expressing hDAT, that this 
channel-like conductance is also associated with the efflux of dopamine induced by 
amphetamine (Kahlig et al., 2005). In other words, amphetamine promotes this 
channel-like mode of conductance and this state of the dopamine transporter 
promotes bursts of dopamine release via DAT in the presence of AMP. It is 
important to note that much slower events were also observed; the authors termed 
these slower events as “transporter-like behavior.” This transporter-like behavior 
was suggested to be associated with reversal of the direction of transport by DAT. 
In contrast, the “channel-like” behavior was characterized by rapid burst-firing 
events. Both of these observed behaviors were shown to be responsible for 
dopamine efflux. The channel-like events could be blocked completely by cocaine 
and cannot be evoked by extracellular dopamine. It was also found that intracellular 
Na+ is a requirement for these channel-like events and that in the presence of 
intracellular Na+ and AMP, the open probability of the DAT channel was increased. 
Further evidence for the connection between these rapid burst-like events and the 
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channel-like properties of DAT was found in comparing the channel flux ratio (ions 
transported per molecule of dopamine in the channel-like mode) with the 
transporter flux ratio (ions transported per molecule of dopamine in the transporter-
like mode); the channel flux ratio is substantially higher than the transporter flux 
ratio. This is to be expected, since the channel-like mode of transported does not 
necessarily require ion binding to the transporter, so the number of ions that can 
pass through is increased. Apart from this channel-like mode of dopamine transport, 
there is another hypothesis for how AMP mediates the release of dopamine from 
neurons via DAT: by direct modification of DAT itself. 
The dopamine transporter contains several serine/threonine residues that 
can be phosphorylated, and this phosphorylation could potentially regulate efflux 
of dopamine mediated by AMP. Experiments in PC12 cells suggest that 
phosphorylation by PKC drives downregulation of DAT at the plasma membrane 
and that phosphorylation by PKC leads to reversible internalization of DAT – 
phosphorylation by PKC leads to trafficking to recycling endosomes (Melikian and 
Buckley, 1999). It has also been demonstrated that inhibition of PKCβ as well as 
the canonical PKC isoforms (α, β1, β2, and γ) can inhibit efflux of dopamine 
mediated by amphetamine in HEK293 cells transfected with DAT. Moreover, it 
was found that PKCβ1 and PKCβ2 are associated with DAT and overexpression of 
PKCβ2 enhances AMP-mediated dopamine efflux (Johnson et al., 2005). However, 
PKCβ requires activation by some intracellular or extracellular signal. How can 
METH or AMP stimulate PKCβ to facilitate dopamine efflux? One possibility is 
that another receptor, one which binds METH and AMP, activates PKC, thus 
mediating dopamine efflux. 
METH and AMPH are agonists of a receptor in the family of receptors 
known as trace amine-associated receptors (TAARs). The receptor known as 
TAAR1 is most relevant to the action of METH and AMP (Liu and Li, 2018). The 
endogenous ligands for this receptor are trace amines such as octopamine and p-
tyramine. As phenethylamines, these compounds are structurally similar to AMP 
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and METH. In HEK293-DAT cells transfected with rhesus monkey TAAR1, both 
METH and dopamine stimulated cAMP production mediated by TAAR1 (Xie and 
Miller, 2007). It was observed that there was an abrupt halt in [3H]dopamine uptake 
in the presence of TAAR1, DAT, and dopamine. This abrupt halt could be 
prevented by PKA and PKC inhibitors. A mutation of residue (T62D) of the DAT 
induced efflux of dopamine, suggesting that phosphorylation of this threonine 
residue can promote a conformation of the DAT amenable to efflux of dopamine 
(Fraser et al., 2014). Additionally, it was observed that both dopamine and 
methamphetamine can increase efflux of [3H]dopamine in the presence of TAAR1 
and DAT but not in the presence of DAT alone. This efflux could be blocked by 
methylphenidate or a PKC inhibitor, in the case of METH. High intracellular 
concentrations of dopamine mediate efflux through a PKC-independent 
mechanism. That METH could not evoke dopamine efflux in the absence of 
TAAR1, suggests that TAAR1 plays a critical role in METH-mediated dopamine 
efflux. 
 These results were recapitulated in studies utilizing WT and TAAR1-/- 
mouse synaptosomal preparation as well as rhesus monkey synaptosomal 
preparation: METH decreased uptake significantly in the WT and rhesus 
preparations while it did so much less in the TAAR -/- preparation. This uptake 
inhibition could be blocked by inhibitors of PKC and PKA. Dopamine release was 
first measured in HEK293-DAT cells. The results suggested that only when 
HEK293-DAT (i.e. not expressing TAAR1) cells are loaded with high 
concentrations of dopamine can release be evoked by METH. The PKC and PKA 
inhibitors blocked TAAR1-mediated effects of METH on dopamine efflux in the 
wildtype synaptosomal preparations and DAT-TAAR1 HEK293 cells that had been 
preloaded with high concentrations of dopamine. Inhibition of PKC and PKA only 
reduced the effect of METH on dopamine efflux in preparations from wildtype 
mice, with no effect observed in TAAR1-/- preparation (Xie and Miller, 2009). 
Thus, both experiments in culture and experiments using tissue support the 
hypothesis that TAAR1 induces dopamine efflux via PKC but not PKA. 
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 Interestingly, TAAR1 activation by AMP could plausibly mediate the 
endocytosis of DAT via RhoA, the latter being activated by the Gα13 G-protein. 
TAAR1 coupled to Gα13 is localized specifically in the endoplasmic reticulum. In 
contrast, activation of PKA mediated by AMP via TAAR1 occurs in a broader set 
of compartments (Underhill et al., 2019). Indeed, robust DAT internalization 
mediated by methamphetamine has been observed in HEK293-DAT-TAAR1 cell 
culture (Xie and Miller, 2009). 
Thus, there are several proposed mechanisms for AMP/METH-mediated 
dopamine release from presynaptic terminals subsequent to redistribution of 
dopamine to the cytosol. The oldest model for AMP-mediated release is the 
facilitated exchange diffusion model and hence there is a substantial body of 
experimental evidence supporting this hypothesis of AMP-mediated dopamine 
release. However, newer hypotheses have emerged, and these hypotheses are 
equally convincing as the facilitated exchange diffusion model. 
1.2.4 Effects on DA Synthesis and Metabolism 
Not only do AMP and METH release dopamine from the presynaptic 
terminals of dopaminergic neurons, they can also alter the synthesis and 
metabolism of dopamine. The most direct mechanism by which they do so is by 
inhibition of monoamine oxidase enzymes. Indeed, METH inhibits the A- isoform 
of monoamine oxidase (MAO-A) as well as the B-isoform of monoamine oxidase 
(MAO-B). This was demonstrated in crab-eating monkey brain mitochondrial 
monoamine oxidase (primarily MAO-B) and synaptosomal monoamine oxidase 
(primarily MAO-A) by utilizing β-phenethylamine as the MAO-B substrate and 
serotonin or dopamine (dopamine is also metabolized by MAO-B) as MAO-A 
substrates. In these experiments, METH was more effective at inhibiting MAO-A 
than MAO-B, and it was also shown that AMP inhibits these monoamine oxidase 
enzymes as well (Egashira et al., 1987). It has been shown that the D-(+) 
enantiomers of both METH (Suzuki et al., 1980) and AMP (Mantle et al., 1976) are 
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superior inhibitors of MAO, particularly MAO-A. The (+) isomer of amphetamine 
has a Ki of 33.8±4 µM at MAO-A and a Ki of 161±32 µM at MAO-B. The (+) 
enantiomer of methamphetamine is an inferior inhibitor of monoamine oxidase 
enzymes, with a Ki of 110±4 µM at MAO-A and 272±83 at MAO-B (Robinson, 
1985). This inhibition of monoamine oxidases prevents the degradation of 
dopamine released from vesicles by METH or AMP, allowing more dopamine to 
be released from the neuron. 
Another potential effect of AMP is that it can increase activity of tyrosine 
hydroxylase (TH), the rate-limiting enzyme in the biosynthesis of dopamine 
(Kuczenski, 1975). In neurons, it has been demonstrated that there are two pools of 
synaptic vesicles, the readily releasable pool (vesicles that are docked to the 
presynaptic membrane) and the reserve pool (a third pool, the recycling pool is less 
relevant to upregulating TH activity). Altering the duration of a train of action 
potentials allows one to distinguish between these two pools – the shorter train 
reveals information regarding the readily releasable pool while the longer train 
reveals information regarding the reserve pool. By varying these train lengths, 
different pools of vesicular dopamine could be interrogated using fast-scanning 
cyclic voltammetry. It was demonstrated in the dorsal striatum that 10 mg/kg 
amphetamine increases dopamine concentrations upon short trains (probing the 
readily releasable pool) and decreases dopamine concentration upon long stimulus 
trains (probing the reserve pool). In the ventral striatum, both 1 mg/kg and 10 mg/kg 
increased dopamine concentration for the short train and the intermediate train, 
indicating an increase in dopamine released from the readily releasable pool and 
the recycling pool. Strangely, there was no decrease in dopamine concentration in 
the reserve pool in the ventral striatum upon trains of action potentials. There was, 
however, a trend towards depletion of dopamine in the reserve pools when tonic 
release of dopamine was examined, supporting the hypothesis that amphetamine 
increases the size of pools that are primed for release while it decreases the size of 
reserve pools (Covey et al., 2013). Indeed, it has been demonstrated that when 
radiolabeled tyrosine is incubated with rat striatal slices, the dopamine that is 
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released is also radiolabeled, since tyrosine is metabolized by TH to L-DOPA and 
then by aromatic amino acid decarboxylase to dopamine. 
This amphetamine-induced enhancement of dopamine synthesis has been 
demonstrated to be calcium dependent, as EGTA (a calcium chelator) injected 
directly into the mouse striatum inhibits the enhancement of radiolabeled dopamine 
synthesis by amphetamine (Fung and Uretsky, 1982). Several intracellular kinases 
are dependent on calcium for full activation. Therefore, it is plausible that a protein 
kinase stimulated by calcium (since EGTA inhibits enhancement of dopamine 
synthesis) is responsible for phosphorylating TH and enhancing its activity. Indeed, 
it has been observed that TH can be modulated by phosphorylation (Dunkley et al., 
2004). It has also been demonstrated that TAAR1 can activate TH when TAAR1 is 
stimulated by 3-iodothyronamine (Zhang et al., 2018), meaning that TAAR1 can 
directly stimulate TH when stimulated. Whether TAAR1 stimulation by METH or 
AMP can directly activate TH is still unknown. 
Thus, AMP and METH not only redistribute dopamine from vesicles to the 
cytosol and promote the release of dopamine, they also have effects on dopamine 
synthesis and metabolism. Inhibition of monoamine oxidase generates conditions 
favorable towards accumulation of free intracellular dopamine while stimulation of 
dopamine synthesis could mediate some of the longer-term effects of AMP and 
METH. 
1.3 Astrocytes 
1.3.1 General Role of Astrocytes in the CNS 
1.3.1.1 History of Astrocytes 
  For many years, it was thought that neurons are the true workhorses of the 
central nervous system and that glia were literally the “glue” that held it together (the 
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word glia is derived from the Greek word for glue). In fact, when the concept of glia 
was first introduced by Virchow in 1856, glia were simply considered the substrate in 
which neural tissue was located. Initially, the cells that constituted glia were called a 
number of different names. Camillo Golgi, using his characteristic silver staining 
method, demonstrated that glia are a population of cells distinct from neurons. The term 
astrocyte was not introduced until 1895 when Michael von Lenhossék used the term to 
describe a subset of parenchymal glia. In fact, the cells with star-like projections and 
end feet encircling small blood vessels observed by Golgi were astrocytes. Late in the 
19th century and early in the 20th century, it was realized that astrocytes are much more 
than the simple “glue” that holds neurons together. Ernesto Lugaro proposed a 
metabolic role for astrocytes, with their fine processes that invade synapses. Carl 
Ludwig Schleich proposed that astrocytes actively control the flow of information. 
Ramon y Cajal suggested that astrocytes regulate the vasculature in the brain by 
constricting or dilating capillaries. One of Ramon y Cajal’s students, Fernando De 
Castro hypothesized that astrocytes release neuroactive substances that can modulate 
synaptic transmission – a precursor of the gliotransmitter hypothesis (Verkhratsky and 
Nedergaard, 2018). 
1.3.1.2 Astrocyte Development 
Astrocytes develop from other astrocytes (via mitosis; certain states, described later 
can promote proliferation  of astrocytes), from progenitor cells called radial glial cells, and 
from NG2 glial cells (Verkhratsky and Nedergaard, 2018). During development, neurons 
and astrocytes are derived from the same neural stem cells. Once these cells have specified 
their fate by expressing several genes, they migrate along radial glial cells (which 
themselves can become astrocytes). Even after radial glial cells retract their processes 
(hence no longer function as scaffolds to direct cell migration), astrocytes still appear to 
migrate during development. When the astrocytes reach their final destination, they begin 
expressing GFAP. Although GFAP can sometimes be an unreliable marker of astrocyte 
maturation and expression levels can vary significantly, GFAP is the gold standard in the 
field; its expression is considered a hallmark of astrocyte identity. However, GFAP 
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expression varies regionally (Chai et al., 2017) and in certain pathological conditions (such 
as Alzheimer’s disease), it can be expressed by neurons (Hol et al., 2003). Other markers 
such as S100β, Aldh1L1, and Glt1 have also been used to identify astrocytes in the past.  
1.3.1.3  Potassium Buffering Roles of Astrocytes 
One important role of astrocytes is to maintain ion homeostasis in CNS tissue. Neurons 
rely on the concentration gradients of Na+ (generally high extracellularly and low 
intracellularly), K+ (generally low extracellularly and high intracellularly), and Cl- 
(generally high extracellularly and low intracellularly) to generate graded and action 
potentials. When a neuron is depolarized in physiological conditions, sodium enters the 
cell and potassium exits the cell. If the depolarization reaches a certain threshold, the cell 
will fire an action potential. During sustained spike trains (several action potentials in a 
short period of time), a significant amount of potassium leaks out of the neuron, increasing 
the extracellular concentration of potassium. If extracellular potassium concentrations are 
too high, the neuron will fire action potentials repeatedly, which can result in seizure-like 
behavior. Astrocytes act as buffers of potassium. Astrocytes are also more permeable to 
potassium than neurons, due in part to high expression of inwardly rectifying potassium 
channels (Kir) that are open at resting membrane potential. Active transport (via Na/K 
ATPase, the same one expressed by neurons) and cotransport (via Na+-K+-Cl- 
cotransporter) mediate entry of potassium into the astrocyte (Kofuji and Newman, 2004). 
In this mode of potassium buffering, individual astrocytes take up excess K+ and store it, 
releasing it back to the extracellular space when extracellular potassium concentrations 
have decreased. Naturally, water is drawn into astrocytes by potassium influx, resulting in 
cell swelling. The other type of extracellular potassium concentration regulation 
demonstrated by astrocytes is spatial buffering. In spatial buffering, potassium ions enter 
astrocytes and travel through the astrocyte syncytium (astrocytes can be coupled to one 
another via ion-permeable gap junctions) to a region where potassium efflux from 
astrocytes is favored. When there is a region of increased [K+]o, potassium ions are driven 
into astrocytes. This depolarization propagates to other astrocytes via gap junctions. In 
regions where [K+]o is low, the driving force (Vm-EK) causes K
+ to flow out of the cell. 
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This redistribution of extracellular potassium is dependent on the efficiency of coupling 
between astrocytes, unlike the net influx form of potassium buffering. 
1.3.1.4  Role of Astrocytes in Glutamate Homeostasis 
 The role of the astrocyte is certainly not restricted only to ion buffering. Astrocytes 
also play a critical role in neurotransmitter uptake, particularly that of glutamate which can 
be excitotoxic at high concentrations. This is particularly important under circumstances 
of high frequency stimulation in which neurotransmitters can “spill over” from the synapse 
and activate extrasynaptic glutamate receptors. In some cases (but not all), extrasynaptic 
glutamate can be neurotoxic and it is associated with neurodegenerative diseases. For 
example, in ischemia, reduced cerebral blood flow leads to ATP depletion which in turn 
inhibits the Na+/K+ ATPase, thus inducing excessive depolarization of neurons and 
subsequent calcium toxicity (i.e. via activation of proteases and induction of apoptosis). 
Excessive calcium entry into neurons also feeds the cycle by promoting the release of the 
excitatory neurotransmitter glutamate. In normal conditions, astrocytes regulate 
extracellular glutamate concentrations by taking up glutamate via EAAT (EAAT/GLAST-
1 and EAAT2/GLT). These proteins are transporters that mediate the influx of sodium, 
protons, and glutamate as well as the efflux of potassium. Relevant to the field of 
psychostimulant abuse, cocaine self-administration has been shown to downregulate GLT-
1 expression and functional activity as well as system xc
- expression and functional activity. 
Administration of the β-lactam antibiotic ceftriaxone restored expression of GLT-1 and 
attenuated cue- or cocaine-induced reinstatement of drug seeking behavior (Knackstedt et 
al., 2010).  Inhibition of the Na+/K+ ATPase during ischemia causes the gradient used for 
cotransporting the molecule of glutamate to collapse and results in an inability of astrocytes 
to take up extracellular glutamate. The cystine-glutamate antiporter is also upregulated 
during ischemia, which contributes to glutamate release from astrocytes. Impaired 
glutamate homeostasis such as that observed in ischemia results in excitotoxicity at 
synaptic sites and extrasynaptic sites, resulting from increases in the calcium permeability 
of neurons, mediated primarily by the NMDA receptors. Activation of extrasynaptic 
NMDA receptors by glutamate overflow from astrocytes generates electrophysiological 
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events known as slow inward currents (SICs). These currents can be distinguished from 
sEPSCs by their much slower kinetics (both rise and decay kinetics) that can be modeled 
using a single exponential function during the decay phase. These SICs, despite being 
mediated primarily by extrasynaptic glutamate receptors (Pál, 2015), are essential for 
modulation of firing in the pendunculopontine nucleus (Kovács and Pál, 2017). Therefore, 
the notion that extrasynaptic glutamate activity is only associated with pathological 
conditions (i.e. apoptosis) is not universally true. These SICs are associated with many 
functions, including synchronization of neuronal circuits (Fellin et al., 2004). 
Apart from the excitatory amino acid transporters, another transporter alters 
extracellular glutamate concentration. This transporter, known as system xc
- mediates 
inward transport of cystine and outward transport of glutamate. Cystine is a necessary 
component of the antioxidant compound glutathione while glutamate is an excitatory 
amino acid neurotransmitter. System xc
- is particularly enriched in glia, both microglia and 
astrocytes (Bridges et al., 2012). System xc
- plays a role in relapse to cocaine seeking 
behavior: during withdrawal from a cocaine self-administration paradigm, extracellular 
glutamate levels decrease, in line with a decrease in the expression of xc
-. Thus, transport 
by xc
- decreases after withdrawal and restoring the function of xc
- after withdrawal (using 
N-acetylcysteine, a cystine prodrug) can inhibit the reinstatement of cocaine-seeking 
behavior by a priming injection of cocaine. The increase in glutamate mediated by system 
xc
- is thought to activate presynaptic group II metabotropic glutamate (Gi/o-coupled) 
receptors which decrease glutamate release and counter reinstatement behavior presumably 
by inhibiting glutamatergic afferents from the prefrontal cortex. Synaptic release of 
glutamate is associated with the reinstatement of drug-seeking behavior, and therefore 
stimulation of these metabotropic glutamate receptors by xc
- decreases reinstatement of 
drug-seeking behavior (Baker et al., 2003). Transport by amino acid transporters is not the 
only proposed mechanism by which astrocytes regulate extracellular glutamate 
concentrations. Briefly, the gliotransmitter hypothesis posits that astrocytes can release 
neurotransmitters in response to stimuli from neurons. In the sections that follow, the 
gliotransmitter hypothesis will be discussed as a proposed mechanism by which astrocytes 
release glutamate. Moreover, astrocytes take up more than just glutamate. They also take 
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up GABA, adenosine (Boison et al., 2010), and glycine. Discussion of these other 
neurotransmitters is beyond the scope of this thesis, but there is a great amount of literature 
discussing these other neurotransmitters (Boison et al., 2010; Schousboe, 2003). Moreover, 
there are several excellent reviews summarizing glutamate homeostasis by astrocytes 
(Rose et al., 2017; Anderson and Swanson, 2000; Hertz et al., 1999; Kalivas, 2009). 
1.3.1.5 Astrocyte Morphology 
 Astrocytes in vivo generally demonstrate a stellate morphology when stained with 
antibodies for glial fibrillary acidic protein (GFAP), a common marker for astrocytes 
(Figure 1.2). The cell body of the astrocyte is generally quite small and the majority of the 
astrocyte surface area is made up of long ramifications on which there are a large number 
of finer processes. These long ramifications are typically visible in brain tissue 
immunostained for GFAP. However, GFAP is expressed heterogeneously among 
astrocytes, and moreover, is not found in the fine processes of astrocytes (Verkhratsky and 
Nedergaard, 2018). This constitutes a critical limitation of utilizing GFAP as a marker to 
visualize astrocytes; up to 95% of the volume contained by an astrocyte is localized in the 
peripheral processes (Shigetomi et al., 2013). Thousands of these extremely fine astrocytic 
processes therefore contribute to the bulk of the volume of astrocytes. Several approaches 
have been employed to view the finer processes of astrocytes that form the perisynaptic 
and endfoot domains of the astrocytes including iontophoresis with Lucifer Yellow (Moye 
et al., 2019) and genetically encoded fluorescent proteins targeted to the plasma membrane 
rather than the cytosol (Testen et al., 2020). These approaches reveal a “cloud” of fine 
astrocytic processes that extend from the main processes of astrocytes. Such processes 
contain calcium microdomains that are highly relevant to studies of astrocyte physiology 
(Shigetomi et al., 2013). Many of these fine processes are often called perisynaptic 
astrocytic processes (PAPs) due to their extremely close proximity to the postsynaptic 
density and the presynaptic terminals of neurons. 
 A key distinction between astrocytes in vivo and astrocytes in monoculture is that 
astrocytes in culture do not normally possess the same stellate morphology. Astrocytes in 
 
21 
 
culture are generally flat and polygonal (Figure 1.3). They can be induced to take on a 
stellate morphology by adding cAMP to the culture media, but this process of stellation 
does not resemble that which occurs during development (Schiweck et al., 2018). 
Astrocytes in culture also take on a more stellate morphology in the presence of dopamine 
(Galloway et al., 2018), possibly via cAMP synthesis induced by D1 receptor activation. It 
is possible to replicate the morphology seen in vivo in culture, complete with fine processes 
that possess calcium transients. This can be achieved by co-culture with neurons with 
added heparin-binding epidermal growth factor or in cultures containing heparin-binding 
epidermal growth factor (HBEGF) and neurobasal medium (media derived from a culture 
of neurons); These astrocytes demonstrated stellate morphology (Wolfes et al., 2017). 
Moreover, when media is supplemented with HBEGF, astrocytes demonstrate calcium 
transients (Morita et al., 2003). 
 Like their microglial counterparts, astrocytes can enter a “reactive” state 
characterized by several phenotypic characteristics. This “reactive” state is just as nebulous 
as it is in microglia (in which reactive microglia were previously classified as M1 or M2), 
and classification of single cells beyond reactive and non-reactive may not be possible 
without rigorous transcriptomic analysis, however, at least one review posits two distinct 
phenotypes of reactive astrocytes (Liddelow and Barres, 2017). The protein GFAP has long 
been utilized as a marker indicating astrocyte reactivity. Part of the reason for why GFAP 
has been utilized as a marker for reactivity is that astrocytes were thought to be highly 
proliferative in the reactive state and indeed in some pathological states, there is dramatic 
upregulation of GFAP. In fact, astrocytes do not exhibit such extreme proliferative activity, 
and there is only a modest increase in proliferation after severe physical injury (i.e. a stab 
wound). Paralleling the classification of reactive microglia, an A1 and A2 type of reactive 
astrocyte have been proposed. The A1 astrocytes typically express pro-inflammatory 
molecules such as TNFα and IL-1β while the A2 astrocytes are immunosuppressant and 
express genes such as Arg1 and Fzd1. Ischemia in particular induces polarization to the A2 
state in which neurotrophic factors are synthesized while inflammatory insults induce 
polarization to the A1 state. Therefore, the A2 state parallels the M2 state of microglia (by 
serving reparative functions) while the A1 state parallels the M1 state of microglia (by 
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serving inflammatory functions). In reality, this polarization may be an extreme 
oversimplification; The M1/M2 polarization of microglia has been called into question, 
and thus, it is plausible that the A1/A2 polarization of astrocytes may also be problematic 
(Ransohoff, 2016). Thus, just as in microglia, the fate of the A1/A2 argument will rely on 
results from single-cell RNASeq (transcriptomic) analyses. 
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Figure 1.2 A max intensity projection of rat prefrontal cortex tissue stained for GFAP 
(red), an astrocytic marker and NeuN (blue), a neuronal marker, viewed with a confocal 
microscope. Astrocytes demonstrate a stellate morphology in vivo. Note that only a 
fraction of astrocytes in the field are stained with anti-GFAP antibody. Image taken by 
Richik Neogi. 
 
Figure 1.3 Astrocytes in culture take on a distinct polygonal morphology. Here tdTomato 
was expressed under the GFAP promoter (image taken by Surya Aryal, reproduced with 
permission) 
1.3.2 Astrocytic Calcium 
Calcium is a unique ion in living systems in that it is also a second messenger. 
While other ions like sodium and potassium exert their effects on a cell primarily via an 
electrochemical gradient, calcium acts as a direct transducer of cell signaling. Intracellular 
calcium concentration varies spatially and temporally in a typical living cell; analysis of 
such calcium transients has become a field in and of itself. Initial studies of astrocytic 
calcium transients involved bulk loading calcium-sensitive, membrane permeable dyes or 
patch dialysis of calcium-sensitive dyes (Russell, 2011). These approaches do not allow 
for visualization of the entire astrocyte and come with their own problems that limit their 
use when analyzing physiologically relevant intracellular calcium signaling. The 
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introduction of genetically encoded calcium indicators (GECI) revolutionized the field of 
astrocyte physiology because these indicators can be expressed throughout the astrocyte in 
different compartments (plasma membrane, cytoplasm, endoplasmic reticulum) which 
allows for visualization of calcium activity in fine astrocytic processes (Tong et al., 2012). 
Introduction of a GECI to a live animal entails surgery and injection of a viral vector 
carrying the GECI gene alongside a promoter (GFAP and GfABC1D are two documented 
promoters for successful expression in astrocytes) directly into brain parenchyma. Since 
the GECI itself is fluorescent, there is no need to employ a reporter to indicate successful 
transfection. This technique is extraordinarily useful because it not only allows for imaging 
in brain slices, but also in vivo imaging. The Lck-GCaMP3 transgene targets the GECI 
GCaMP3 specifically to the plasma membrane. Using an AAV2/5 vector, Shigetomi and 
coworkers (Shigetomi et al., 2013) successfully achieved hippocampal expression of Lck-
GCaMP3 and cyto-GCaMP3. The Lck-GCaMP3 animals, in particular, revealed the 
presence of calcium microdomains in the fine astrocytic processes that previously could 
not be effectively visualized. The Lck-GCaMP3 animals expressed GCaMP3 in a “cloud” 
surrounding the astrocyte soma whereas the cyto-GCaMP3 animals expressed GCaMP3 in 
a more traditional fashion (similar but not identical to that revealed by GFAP IHC). Both 
were expressed in the entire astrocytic territory. Analysis of calcium activity using GECIs 
and the calcium indicator Fluo-4AM revealed that the GECIs revealed a greater number of 
calcium events than the organic calcium indicator. 
Calcium transients in astrocytes are not simply epiphenomena of astrocyte 
physiology; they play a direct role in brain function. The gliotransmitter hypothesis posits 
that astrocytes can release substances that can influence neurotransmission; this hypothesis 
will be the subject of the next section. Another function of calcium in astrocytes is to 
promote vasodilation of cerebral vasculature via activation of the calcium-dependent 
phospholipase A2 (cPLA2) which releases arachidonic acid from membranes. This 
arachidonic acid is processed to prostaglandins by cyclooxygenase. Prostaglandins dilate 
vasculature. It was demonstrated that stimulation of Gq-coupled metabotropic glutamate 
receptors releases prostaglandin and is also associated with vasodilation (Zonta et al., 
2003), although there is some evidence that astrocytic calcium signaling induced by Gq is 
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too slow to account for stimulus-induced vasodilation and that mice lacking the gene for 
the major inositol triphosphate receptor mediating calcium release from the ER (IP3R2) 
still exhibit stimulus-induced vasodilation (Nizar et al., 2013). 
In astrocytes, calcium can enter the cytosol from three different compartments. It 
can enter through the plasma membrane by calcium channels driven by the electrochemical 
gradient between the cytosol and the extracellular fluid, it can enter by release from the 
endoplasmic reticulum via inositol triphosphate (IP3R) or ryanodine receptors (RyR), or it 
can be released from the mitochondria, particularly when the cell is apoptotic. A fourth 
form of calcium entry can be mediated by connections with other astrocytes (through gap 
junctions).  
Astrocytes express a variety of calcium channels. In addition to channels such as 
Orai, which serve to replenish intracellular (endoplasmic reticulum) stores of calcium, 
astrocytes also express voltage-gated calcium channels (VGCCs). Voltage-gated calcium 
channels can be divided into four classes based on electrophysiological and 
pharmacological properties. The L-type calcium channel has been proposed to promote the 
“reactive” state of astrocytes, and indeed LPS-induced reactivity is associated with a 
proportionate increase in Cav1.2 expression (Cheli et al., 2016). However, the distribution 
of VGCCs in astrocytes is not uniform across all brain regions. Ligand-gated calcium 
channels such as the P2X receptors also can plausibly mediate calcium entry into 
astrocytes. The P2X7 receptor, activated by high concentrations of ATP, can mediate pro-
inflammatory functions of astrocytes (Panenka et al., 2001) and moreover, activation of 
glial P2X7 receptors can modulate synaptic activity in the hippocampus (Khan et al., 2019). 
The subject of ion channels on astrocytes has been reviewed in detail elsewhere 
(Verkhratsky and Steinhäuser, 2000). The form of calcium entry that has been supported 
by the largest amount of evidence, however, is that mediated by release from the 
endoplasmic reticulum. 
 Activation of Gq coupled GPCRs initiates an intracellular cascade that 
results in the release of inositol triphosphate (IP3) and diacylglycerol (DAG) from 
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phospholipids at the plasma membrane via the action of phospholipase Cβ. The second 
messenger IP3 then activates IP3 receptors (IP3Rs) located in the membrane of the 
endoplasmic reticulum, resulting in the release of calcium from intracellular stores. 
Activation of a wide variety of Gq coupled receptors can initiate calcium activity in 
astrocytes including glutamate (Sun et al., 2013), GABAB (Mariotti et al., 2016), dopamine 
D1 (Liu et al., 2009), and P2Y (Gallagher and Salter, 2003) receptors. Depending on spatial 
and temporal localization, ligands for these receptors can have differential effects on 
calcium transients. For example, the P2Y2 receptor promotes more rapidly traveling 
calcium waves than the P2Y1 receptor, however the nucleotidase apyrase blocks the 
calcium waves produced by P2Y2 receptor activation, but enhances those produced by 
P2Y1 receptor activation (Gallagher and Salter, 2003). The specific isoform of the IP3R 
that is associated with calcium transients in astrocytes has been proposed to be IP3R2 
(Petravicz et al., 2014). Experiments by this group in which IP3R2 was knocked out 
suggested that Gq-mediated calcium signaling was abolished. Indeed, knockout mice 
(IP3R2 -/-) survive to maturity and there was a significant reduction in the frequency, 
amplitude, and duration of somatic calcium transients (Srinivasan et al., 2015). However, 
there was a much less pronounced effect in the processes of astrocytes, which constitute 
the bulk of the volume contained by astrocytes. The frequency of calcium transients was 
not significantly reduced. The duration of calcium transients in the processes was increased 
in IP3R2 (-/-) mice and the amplitude was significantly decreased. Knockout of IP3R2 did 
not decrease the mean fluorescence of averaged traces compared to WT mice. The 
contribution of transmembrane calcium flux was quantitated using calcium-free buffer – it 
was found that calcium-free buffer abolished calcium waves and reduced the basal intensity 
of calcium signals. It is therefore plausible that transmembrane flux of calcium plays a role 
in calcium transients, perhaps those mediated by the TRPA1 channel (Shigetomi et al., 
2011). 
 However, IP3R2 knockout could not abolish calcium transients in the peripheral 
processes evoked by endothelin, a ligand for a Gq-coupled receptor. It was observed that 
only somatic calcium fluctuations mediated by the endothelin receptor could be abolished. 
In live unanesthetized animals, it was observed that the frequency of calcium events in 
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microdomains (located in the processes of astrocytes primarily) was slightly but 
significantly reduced, the amplitude was increased, and the duration of these calcium 
events was unaffected by IP3R2 knockout (Srinivasan et al., 2015).  
Thus, there is robust evidence that intracellular calcium transients occur in 
astrocytes, even with astrocytes in physiological conditions. Both GECIs and calcium-
sensitive dyes can detect these calcium transients, but GECIs do so more effectively 
because they reach all parts of the astrocytes, including the fine processes. The precise 
function of these transients in the cell is currently unknown; whether these calcium 
transients are responsible for the release of gliotransmitters is a matter of debate in the 
field, with one camp insisting that gliotransmitter release occurs in vivo (Savtchouk and 
Volterra, 2018) and the other insisting that it does not occur in physiological conditions 
(Fiacco and McCarthy, 2018).  
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CHAPTER 2. THE SIGMA-1 RECEPTOR 
2.1 Molecular Biology and History of the Sigma-1 Receptor 
 The sigma receptors were initially characterized as novel subtypes of the opioid 
receptor family based on studies that revealed the existence of multiple subtypes of opioid 
receptors in the spinal dog (Martin et al., 1976). In these studies, morphine was 
characterized as the prototypical µ-opioid receptor agonist, ketocyclazocine as the 
prototypical κ-opioid agonist, and the benzomorphan SKF-10,047 as the prototypical σ-
receptor agonist. It was later determined that SKF-10,047 binds to sites in the guinea pig 
brain that are not accessible to the potent opioid ligand etorphine, and that this binding 
could not be occluded by the opioid antagonist naltrexone (Su, 1982). Thus, the “σ-opioid 
receptor” was renamed the σ-receptor (Su et al., 1988). 
 The sigma-1 receptor (herein referred to as the S1R) was first successfully cloned 
in 1996 (Hanner et al., 1996). The corresponding mammalian open reading frame encodes 
a protein of mass 25.3 kDa with at least one transmembrane segment. The primary structure 
of the protein contains a putative endoplasmic reticulum retention signal (WAVGRR), and 
shares sequence homology (67% sequence homology) with a fungal C8-C7 sterol 
isomerase, but does not share sequence homology with any other known mammalian 
protein (Moebius et al., 1997). 
 The structure of the S1R has been the subject of debate since its discovery. 
Computational algorithms predict the presence of two to three transmembrane domains 
(Bolshakova et al., 2016), and some experimental evidence suggests the presence of two 
transmembrane domains (Aydar et al., 2002; Mori et al., 2013). In the study by Aydar and 
coworkers, GFP was fused either to the C-terminus or the N-terminus. In Xenopus oocytes, 
the fluorescence was localized towards the cytoplasmic face of the plasma membrane for 
both constructs. This suggests the existence of an even number (i.e. two) of transmembrane 
segments, as the constructs would differ in terms of fluorescence localization if there were 
an odd number of transmembrane segments. Nevertheless, the x-ray crystallographic 
structure of the human S1R reveals an assembly of three protomers, each with a single 
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transmembrane domain; this directly contradicts the findings suggesting two 
transmembrane domains (Schmidt et al., 2016). 
2.2 Sigma-1 Receptor Ligands 
 The S1R is a unique receptor in that its mode of signal transduction does not rely 
on commonly known signal transduction cascades (i.e. those mediated by G-proteins or 
receptor tyrosine kinases). Rather, its “activity” is characterized by association with various 
partner proteins upon binding of a ligand. This has led to the classification of the S1R as a 
“ligand-regulated non-ATP binding membrane-bound chaperone protein (Chu and Ruoho, 
2016).” Moreover, ligands for the sigma-1 receptor are structurally diverse (Figure 1.1 and 
Figure 1.2) 
 Helices in the C-terminal region of the S1R are responsible for interaction with 
binding immunoglobulin protein (BiP), and it is thought that binding of ligand to the 
receptor alters the ability of the S1R to form oligomers (Gromek et al., 2014) via a GXXXG 
motif at the C-terminus. Before addressing whether certain ligands are agonists, 
antagonists, or inverse agonists, it is important to determine the structural requirements for 
a compound to be a ligand of the S1R.  
A triple-mutant S1R with alanine substitutions at L105, L106, and S93 
demonstrated markedly reduced binding to NE-100 as did a mutant with a phenylalanine 
substitution at Y103 and an alanine substitution at S93 also demonstrated similarly reduced 
binding. Interestingly, the triple-mutant S1R did not demonstrate reduced affinity for the 
S1R agonist (+)-pentazocine (Yamamoto et al., 1999), suggesting differences in the 
binding requirements for agonists (pentazocine) and antagonists (NE-100).  
 With the exception of the cholesterol-based ligands of the S1R (which bind to a 
distinct site separate from other ligands), all known S1R ligands possess a basic nitrogen 
atom that is critical for interaction with the S1R. Removal of the nitrogen atom from 
phenalkylpiperidine derivatives abolished S1R binding (Ablordeppey et al., 2000). Indeed, 
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the presence of a basic nitrogen atom flanked by two longer hydrophobic moieties has been 
termed the minimal S1R-binding pharmacophore (Schmidt et al., 2018). The notion that a 
basic nitrogen atom is critical for ligand binding was confirmed when cells treated with the 
crosslinking reagent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) expressed 
dramatically reduced affinity for radiolabeled haloperidol and radiolabeled pentazocine. In 
this context, crosslinking reagents are those that facilitate peptide bond formation between 
a sidechain carboxyl group and a free amino group. These findings were corroborated by 
the observation that the S1R mutants D126G and E172G demonstrated only 9% and 3% of 
the binding to [3H]haloperidol relative to the wild-type control (Seth et al., 2001). In fact, 
both agonists and antagonists of S1R require the presence of E172, as revealed by an x-ray 
crystallography study assessing the pose and interactions with the S1R of NE-100, 
haloperidol, and (+)-pentazocine (Schmidt et al., 2018). However, antagonists and agonists 
differ in terms of their binding to other regions of the S1R. Per the minimal S1R-binding 
pharmacophore, antagonists take on a linear pose in the binding site with the primary 
(longer) hydrophobic arm pointed between α-helix 4 (α4) and α-helix 5 (α5). The shorter 
hydrophobic arm of the antagonist occupies the space near D126. In contrast, for the 
agonist (+)-pentazocine (and likely for all S1R agonists containing a basic nitrogen), 
binding forces α4 away from α5. Moreover, S1R agonists generally have a nonlinear 
structure. Thus, in the antagonist-bound state, α4 adopts a similar position to that of the 
ligand-free S1R. In the agonist-bound state, S1R must undergo a conformational change to 
prevent steric clash with the ligand. The authors verified that other agonists bind in this 
manner by docking PRE-084 to S1R, indicating that this conformational change is required 
for broader efficacy of all S1R agonists. In kinetic experiments measuring the on and off 
rate of (+)-pentazocine and haloperidol, it was determined that there was a rate-limiting 
step that was ligand-independent, meaning that for binding to occur, S1R must adopt a 
proper conformation. Through MD simulation experiments, it was found that binding 
pathway requires two conformational changes in the structure of S1R, independent of the 
ligand. These states were reversible, suggesting that binding is stochastic; in order for an 
agonist to bind, the receptor must occupy a certain conformational state. 
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 The S-(+) isomer of methamphetamine is a ligand at the S1R with an affinity 
comparable to that of cocaine (2 µM in the mouse brain in competition with pentazocine 
for cocaine and 2.16 µM in the rat brain in competition with pentazocine for 
methamphetamine). There is conflicting data regarding whether methamphetamine is an 
agonist or an inverse agonist at the sigma-1 receptors. Agonists of the S1R normally induce 
dissociation of S1R from binding of immunoglobulin (BiP). Methamphetamine increased 
the association of BiP with S1R, as demonstrated by co-immunoprecipitation experiments, 
although this finding failed to reach significance (p > 0.05) while (+)-pentazocine and PRE-
084 significantly induced dissociation of BiP from S1R (Hayashi and Su, 2007). 
Interestingly, cocaine did not significantly alter the association of S1R with BiP either, 
suggesting that this assay may not be able to unambiguously distinguish weak agonists 
from antagonists. Thus, the identity of various ligands as agonists or antagonists is still up 
for debate, as these results clearly show that some agonists do not dissociate S1R from BiP 
while others do. The previously cited affinities of methamphetamine and cocaine for the 
S1R are near to those reached in physiologically relevant cocaine or methamphetamine 
administration paradigms (Yasui and Su, 2016). Many of the behavioral effects of cocaine 
(i.e. cocaine-induced CPP) are attenuated by administration of S1R antagonists such as 
NE-100 and BD-1047 (Romieu et al., 2001). Similarly, administration of MS-377, a S1R 
antagonist, attenuates the development of locomotor sensitization to methamphetamine 
(Takahashi et al., 2000). There is however, some conflicting data on whether it is an agonist 
or an inverse agonist for S1R based on cellular data. Methamphetamine behaves as a an 
S1R agonist behaviorally while there is conflicting evidence for its actions at the S1R 
receptor at a molecular and cellular level. 
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Figure 2.1 Sigma-1 receptor agonists are structurally diverse; most possess nonlinear 
structures 
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Figure 2.2 Sigma-1 receptor antagonists possess a more linear structure than agonists 
2.3  Sigma-1 Receptor and DA Signaling 
 Given that two major psychostimulants (METH and cocaine) are both ligands of 
the S1R, one can speculate that the effects at the S1R could alter dopamine receptor 
signaling or uptake of dopamine by DAT since the S1R is known to interact with GPCRs 
(Kim et al., 2010) and many other client proteins. Indeed, BRET experiments in HEK293T 
cells suggest that S1R forms a heteromer with the D1 dopamine receptor and the agonist-
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bound form of S1R stabilizes the outward-facing conformation of dDAT, enhancing 
binding of cocaine in the process (Hong et al., 2017). 
 That the S1R interacts with DAT is particularly relevant to mechanisms of 
psychostimulant action, since two major psychostimulants, cocaine and methamphetamine, 
are ligands of the S1R as well as DAT. In rat brain tissue, the sigma-1 receptor agonists 
PRE-084 and (+)-pentazocine increased the Bmax of [
3H]WIN35428 (a DAT inhibitor) 
without altering Ki and both drugs also increased the Vmax of dopamine transport by DAT 
in low sodium conditions (conditions unfavorable towards inward transport by DAT). It 
was also shown in HEK293 cells transfected with dDAT that S1R forms a heteromer with 
DAT, much like the S1R does with D1 receptors. When proteins change conformation, 
sometimes cysteine residues become exposed to the extracellular milieu. It is possible to 
manipulate this change in accessibility using a cysteine accessibility assay. In this assay, 
when a drug is added, the conformation of the protein changes in a way that exposes 
cysteine residues to a thiol-reactive reagent. It was found that PRE-084, only in the 
presence of cocaine, increased C306 accessibility. This increase was abolished by 
treatment with a selective S1R antagonist (Hong et al., 2017). This study also recapitulated 
the idea that S1R forms higher order oligomers upon treatment with antagonists and can 
only interact with DAT in the form of lower order S1R oligomers (dimers and monomers).  
 Some studies suggest that activation of the sigma-1 receptor during exposure to 
methamphetamine opposes the behavioral and cellular effects of METH such as locomotor 
sensitization and METH-mediated dopamine efflux. Treatment with PRE-084, a S1R 
agonist, or upregulation of the S1R during exposure to methamphetamine in the bath 
inhibits METH-stimulated firing activity in dopaminergic neurons. Moreover, treatment 
with 1 µM PRE-084 decreased METH-mediated dopamine efflux in vivo and in vitro while 
BD1063 had no effect. The study found that S1R colocalizes with DAT at the plasma 
membrane, and its association with DAT is increased when METH is present in the bath 
(Sambo et al., 2017). That S1R is found to be localized at the plasma membrane associated 
with DAT and that METH alone produced no change in the localization provides an 
argument against the assumption that METH is an inverse agonist at S1R, since an inverse 
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agonist would increase the number of higher-order (DAT unassociated) oligomers which 
in turn would localize at the ER. Some studies have suggested that intracellular calcium is 
necessary for dopamine efflux induced by AMP via DAT as well as inward currents 
mediated by AMP (Gnegy et al., 2004). Indeed, AMP can increase [Ca2+]i in a DAT-
dependent manner. This increase in intracellular calcium could be blocked by depleting 
calcium in the ER using thapsigargin, suggesting that the increase in  calcium is not due to 
transmembrane flux, but rather due to release from the ER, although there is evidence to 
suggest that the increase in intracellular calcium was only observed in the presence of 
extracellular calcium (Mundorf et al., 1999). In the work by Sambo and coworkers, neurons 
either expressing GCaMP6f or loaded with Fura-2-AM were assessed for calcium activity 
in the presence of METH and/or PRE-084. It was observed that METH alone increased 
intracellular calcium and this increase could be blocked by the DAT inhibitor nomifensine. 
This increase could also be blocked by the S1R agonist PRE-084. This study also revealed 
that PRE-084 attenuated behavioral responses (ICSS, CPP, and locomotor activity) to 
methamphetamine administered by the experimenter (Sambo et al., 2017), although the 
S1R antagonist BD-1063 also attenuated these responses. Interestingly, a previous study 
examining the effects of S1R agonists on methamphetamine-induced behavior found that 
the S1R agonist SA4503 attenuated radiolabeled dopamine efflux, yet it potentiated some 
behaviors associated with methamphetamine such as those during drug-discriminatory 
tasks and also attenuated others such as locomotor activation. However, S1R antagonists 
BD1047 and BD1063 had no effect on radiolabeled dopamine efflux (Rodvelt et al., 2011).  
 The S1R forms oligomers with several GPCRs such as the mu-opioid receptor (Kim 
et al., 2010) and modulates the activity of the GPCR. It has been demonstrated that the D1 
dopamine receptor also interacts with S1R and S1R interaction with D1R can modulate the 
activity of the D1R. Agonists at the S1R can enhance PKA activation in rat synaptosomal 
preparation (from the prelimbic cortex) through the D1R in the presence of a selective D1R 
agonist. This effect was clearly mediated by the S1R because it was abolished by 
incubation with a S1R antagonist. The S1R agonist enhanced PKA activation in the 
presence of a cell-permeable cAMP analog and in the presence of forskolin, an adenylyl 
cyclase activator, but did not enhance adenylyl cyclase stimulation by Gs in the presence 
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of a dopamine D1 receptor agonist. This suggests that S1R could act somewhere 
downstream of the receptor itself to enhance PKA activation. This increase in PKA 
activation by S1R agonist could be blocked by incubation with the PKC inhibitor 
chelerythrine as well as incubation of synaptosomes in EGTA-containing buffer, 
suggesting that PKC and calcium mediate the effect on PKA activation. Moreover, 
blockade of voltage-gated calcium channels also abolished the effect of S1R agonist on 
PKA activation, suggesting that the source of this calcium is transmembrane flux. It was 
demonstrated that PKC is upstream of the increase in intrasynaptosomal calcium, and that 
chelerythrine abolished the increase in calcium concentration. Incubation with the ER 
calcium-depleting agent thapsigargin had no effect on the increase in intrasynaptosomal 
calcium mediated by S1R activation (Fu et al., 2010). Interestingly, PKC in astrocytes has 
been implicated in mediating long-lasting behavioral sensitization induced by 
methamphetamine. Moreover, incubation of cultures with 10 µM methamphetamine 
(within the range considered “physiological”) increased stellation that could be partially 
abolished by treatment with a PKC inhibitor. Similarly, incubation with this concentration 
of methamphetamine also increased GFAP immunoreactivity and intracellular calcium 
activity evoked by 10 µM of dopamine and glutamate (Narita et al., 2005). 
 To investigate the effects of the S1R-D1 receptor action in cocaine administration, 
Navarro and colleagues utilized a variety of techniques to demonstrate the existence of a 
D1-S1R heterooligomer and assessed cocaine’s effects on this oligomer (Navarro et al., 
2010). In HEK293T cells, BRET (between σ1-YFP and D1-Rluc) was utilized to determine 
the existence of heterooligomers and indeed it was determined that a heterooligomer 
between the S1R and D1 receptor exists in cell culture. Moreover, treatment with cocaine 
induced translocation of S1R to the plasma membrane and colocalization with the D1 
receptor. Utilizing a D1-YFP and D1-Rluc pair, the BRET signal was reduced dose-
dependently in the presence of cocaine, suggesting that S1R receptor activation disrupts 
D1 receptor homodimers. In CHO cells, cocaine robustly enhanced cAMP accumulation 
induced by treatment with a selective D1 receptor agonist. When CHO cells were treated 
with cocaine alone, there was no increase in cAMP accumulation, however, when they 
were treated with cocaine and SKF-81297, a D1 receptor agonist, there was potentiation of 
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cAMP accumulation. Similarly, D1 receptor-mediated phosphorylation of ERK1/2 by 
activation via SKF-81297 could be blocked by administration of PD-144,418, an S1R 
antagonist. Cocaine and PRE-084 could increase the phosphorylation of ERK1/2 in the 
absence of a D1 receptor ligand. However, in combination with a D1 receptor agonist (SKF-
81297), cocaine and PRE-084 counteracted the increase in ERK1/2 phosphorylation by 
SKF-81297. The results from the cAMP accumulation and ERK1/2 phosphorylation 
experiments were recapitulated in slices from mouse striatum; incubation with either the 
D1 receptor agonist or cocaine increased phosphorylation of ERK1/2. Moreover, in striatal 
slices from S1R knockout animals, cocaine was unable to induce ERK1/2 phosphorylation. 
Therefore, when present in this heterooligomeric form with the D1 receptor, the sigma-1 
receptor can phosphorylate ERK1/2 alone, but when both a sigma-1 receptor agonist and a 
D1 receptor agonist are present, ERK1/2 phosphorylation is counteracted, suggesting an 
antagonistic interaction between the two receptors. A potential area of further research 
would be to observe if these findings can be recapitulated in pure astrocyte culture or 
astrocyte-rich cell culture. 
 The S1R also forms complexes with the dopamine D2 receptor, however in this 
case, the S1R turns down signaling via the D2 receptor (Navarro et al., 2013). Like in the 
previous report regarding D1 receptors, D2/D3/D4 receptors were fused to Rluc and σ1 
receptors to YFP. A significant BRET signal was observed with D2 receptors but not with 
D3 or D4 receptors in HEK293T cells. Moreover, after transfection with D2 receptor cDNA, 
colocalization between S1R and D2 receptors was detected. In cells expressing both Rluc-
S1R and YFP-S1R, homodimers between S1R protomers were detected via BRET and 
heterooligomers of S1R with D2 receptor homodimers were detected as well. 
Diheterotetramers (S1R-S1R-D2-D2) were detected using a modified BRET protocol. 
Further BRET experiments revealed that activation of the S1R induces changes in the D2-
D2 homomers and in the S1R-D2 heteromers. In functional assays using CHO cells, it was 
determined that cocaine alone does not elicit any changes in D2 receptor signaling, but 
there is a small but significant decrease in  D2 receptor signaling when cells were pretreated 
with cocaine (30 µM) and then treated with increasing concentrations of quinpirole. 
Moreover, cocaine significantly decreased the D2-mediated decrease in forskolin-
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stimulated cellular cAMP evoked by the D2 receptor agonist quinpirole. This effect was 
also observed when PRE-084 was utilized in lieu of cocaine. However, when both 
quinpirole and cocaine were incubated with cells at the same time, negative cross-talk was 
detected, indicating an antagonistic interaction between the two receptors. It was also 
determined that activation of the S1R in the D2-S1R heteromer can induce phosphorylation 
of ERK1/2 and that the D2 antagonist raclopride or S1R antagonist PD144418 could inhibit 
ERK1/2 phosphorylation. To investigate whether these results could be recapitulated in 
mouse striatum, first, a Western blot and coimmunoprecipitation experiment were 
conducted. It was found that S1R was detected in WT but not S1R KO mouse striatum and 
D2 receptors were expressed in both groups. The coimmunoprecipitation experiments 
revealed that the S1R does indeed form stable oligomers with the D2 receptor. A proximity 
ligation assay also confirmed that the S1R formed stable oligomers with the D2 receptor 
and that these results were not artifacts of detergent solubilization. Moreover, the 
antagonistic interaction on ERK1/2 phosphorylation was also observed in mouse striatal 
tissue: incubation with both quinpirole and cocaine abolished ERK1/2 phosphorylation, 
but when incubated with either compound alone, an increase in ERK1/2 phosphorylation 
was observed.  
 Thus, the sigma-1 receptor interacts directly with both the D1 and D2 receptors. It 
has also been suggested that the sigma-2 receptor interacts with the D1 receptor but not the 
D2 receptor. While the sigma-2 receptor is beyond the scope of this chapter, it is important 
to note that it does interact with the D1 receptor exclusively. Evidence suggests that the 
sigma-1 receptor may form a heterotrimeric complex with the sigma-2 and D1 receptors. 
When siRNA for the sigma-1 receptor was introduced to HEK293T cell culture (thus 
disrupting the heterotrimeric complex), cocaine and an agonist for the sigma-2 receptor 
reduced cAMP formation in the presence of a D1 receptor agonist. Conversely, when 
siRNA for the sigma-2 receptor was introduced, cocaine potentiated agonist-induced 
cAMP formation. In cells lacking the sigma-1 receptor, but expressing D1 receptor and 
sigma-2 receptor, cocaine pretreatment potentiated ERK1/2 phosphorylation via a D1 
receptor agonist. In cells that expressed the sigma-1 receptor and D1 receptor but not the 
sigma-2 receptor, cocaine inhibited ERK1/2 phosphorylation via a D1 receptor agonist. 
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Moreover, when all three receptors (sigma-1, sigma-2, and D1) were expressed in cell 
culture, there was no effect of cocaine on cAMP accumulation or ERK1/2 phosphorylation, 
suggesting an antagonistic interaction between the sigma-1 receptor and sigma-2 receptor 
on the D1 receptor. In striatal sections from rats injected acutely or chronically with 
cocaine, differences were observed in terms of the number of cells expressing D1-σ1 
oligomers or D1-σ2 oligomers. For cocaine-naïve animals, 38.5% of cells expressed D1-σ1 
oligomers and 25% of cells expressed D1-σ2 oligomers. In animals acutely treated with 
cocaine, the number of both oligomeric complexes (measured by counting puncta) was 
increased, but 54% of cells expressed D1-σ1 oligomers and 33% expressed D1-σ2 oligomers. 
When animals were treated chronically with cocaine, the number of D1-σ1 oligomeric 
complexes and the number of cells expressing D1-σ1 oligomers were restored to that of 
cocaine-naïve animals, but the number of D1-σ2 oligomeric complexes remained elevated 
and the number of cells expressing D1-σ2 complexes remained approximately the same. 
These results suggest that acute administration of cocaine drives increases in primarily the 
D1-σ1 oligomers, but chronic administration of cocaine drives an increase in D1-σ2 receptor 
oligomers (Aguinaga et al., 2018). 
 
2.4 Physiology of the Sigma-1 Receptor 
2.4.1 Sigma-1 Receptor Localization 
 The sigma-1 receptor is primarily an ER-localized protein. In particular, it is 
enriched at the mitochondrial associated membrane (MAM), the junction between 
mitochondria and the ER, where it can regulate calcium flux into mitochondria by 
associating with IP3 receptors. It forms raft-like microdomains enriched in cholesterol on 
the ER and is thought to regulate lipid transport from the ER to the plasma membrane; 
treatment with (+)-pentazocine causes these sigma-1 receptor-containing microdomains to 
disappear (Hayashi and Su, 2003). In normal, agonist-free conditions, the sigma-1 receptor 
at the ER is bound to binding of immunoglobulin protein (BiP), a molecule involved in the 
response to unfolded proteins. It was observed in CHO cells that upon calcium depletion 
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(by ATP via P2Y receptors, by treatment with thapsigargin, or by treatment with the 
calcium chelator BAPTA), the S1R dissociates from BiP and forms complexes with IP3R3. 
Treatment with (+)-pentazocine after thapsigargin-mediated calcium depletion increases 
the coupling between S1R and IP3R3 (Hayashi and Su, 2007). A previous study suggested 
that ankyrin B (particularly the ankyrin 220 isoform), IP3R3, and the S1R associate in the 
ER (see Figure 2.3). Treatment with (+)-pentazocine evoked dissociation of S1R from 
ankyrin B and presumably IP3R3, since this treatment also caused the S1R to disappear 
from the P3L (ER-enriched) fraction and translocate to the plasma membrane (Hayashi and 
Su, 2001). 
   
 
Figure 2.3 Agonists promote the formation of lower order oligomers which can interact 
with other protein clients. Inverse agonists and antagonists promote the formation of 
higher-order oligomers which represent the inactive state of the receptor (Chu and 
Ruoho, 2016). Red circles represent the states that can interact with protein clients while 
blue represents the inactive state. 
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Figure 2.4 The interaction between IP3R3, the sigma-1 receptor, and ankyrin occurs in the 
basal, unstimulated state. Upon sigma-1 receptor binding (blue circle), ankyrin and the 
sigma-1 receptor dissociate from IP3R3 and this allosterically potentiates IP3R3, 
increasing efflux of calcium. Since IP3 (red circle) concentrations at basal state are not 
high enough to stimulate efflux of calcium, there would initially be no calcium release. 
Upon addition of the sigma-1 receptor agonist, the IP3R becomes more sensitive to 
intracellular IP3 concentration. This may enable the IP3R receptor to become active in 
basal state, but evidence suggests that Gq-coupled receptor stimulation is required to fully 
observe the potentiating effect of the sigma-1 receptor (Hayashi and Su, 2001). Image 
created in Biorender. 
 Sigma-1 receptor ligands can also regulate the homo-oligomeric status of the S1R 
(Chu and Ruoho, 2016). In physiological conditions, the intracellular population of the S1R 
is distributed among monomeric and oligomeric states. There is evidence that the S1R may 
be constitutively active, based on findings that demonstrated that the sigma-1 receptor can 
release inhibition of G-protein mediated signaling; overexpression of the sigma-1 receptor 
can increase bradykinin-mediated intracellular calcium release in the absence of agonists 
for the bradykinin receptor. Inverse agonists like BD-1063 bias the population S1R towards 
higher order oligomers while agonists bias the population of lower order oligomers (Figure 
2.3). The dimers are thought to allow S1R to form chaperone complexes, while the 
monomers are thought to allow S1R to form chaperone complexes and complexes with 
protein partners (Chu and Ruoho, 2016). It was also demonstrated that sigma-1 receptor 
agonists can induce translocation of the sigma-1 receptor to focal adhesion contacts at the 
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plasma membrane in CHO cells (Mavlyutov and Ruoho, 2007). Interestingly, stabilization 
of F-actin filaments dramatically enhanced the number of S1R at the plasma membrane, 
suggesting that the actin cytoskeleton may play a role in translocation of the S1R.  
2.4.2 Sigma-1 Receptor and IP3 Receptors 
 As stated in the previous section, the sigma-1 receptor responds to calcium 
depletion in the ER by increasing its coupling with IP3R3. Moreover, sigma receptor 
agonists induce dissociation of the S1R and IP3R from ankyrin B (Hayashi and Su, 2001). 
This dissociation alone was not found to increase cytosolic calcium concentrations, 
however, in the presence of an agonist for a Gq-coupled receptor (bradykinin) of thus, 
presumably increased IP3 concentrations, various sigma-1 receptor agonists enhanced the 
increase in cytosolic calcium (although it has been observed that the sigma-1 receptor 
agonist BD-737 alone can increase IP3 synthesis in cardiac myocytes; see Novakova et al., 
1998). In the work by Hayashi and Su in 2001, it was determined that dissociation of 
ankyrin from IP3R increased the binding of [
3H]IP3, suggesting that sigma-1 receptor-
mediated dissociation of ankyrin from IP3R can potentiate calcium efflux from the ER by 
increasing binding of IP3 to IP3R. The potentiation of bradykinin-induced calcium release 
was determined to occur in a bell-shaped manner with respect to S1R agonist 
concentration, and was unaffected by removing calcium from the bath solution (Hayashi 
et al., 2000). Importantly, three different agonists (PRE-084, pentazocine, and 
pregnenolone sulfate) of the S1R increased bradykinin-potentiated calcium release from 
the ER. The effect of PRE-084 on intracellular calcium was abolished by the S1R 
antagonist NE-100 and the effects of the other ligands were abolished by knockdown of 
the S1R. In these experiments, no potentiating effect on intracellular IP3 concentration was 
observed, although (+)-pentazocine increased the ceiling of bradykinin-induced IP3 
formation. Although discussion of the protein chaperone role of the sigma-1 receptor is 
beyond the scope of this manuscript, it should be noted that the sigma-1 receptor prevents 
proteasomal degradation of the IP3 receptor. Knockdown of the sigma-1 receptor revealed 
prominent proteasomal degradation of IP3R3 upon ATP stimulation of P2Y2 receptors 
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(Hayashi and Su, 2007). Thus, the sigma-1 receptor modulates IP3R3 at multiple levels. It 
can directly enhance activation of IP3R3 and it can also prevent degradation of IP3R3. 
2.4.3 Sigma-1 Receptor and Store-Operated Calcium Entry (SOCE) 
 When intracellular stores of calcium are depleted, STIM1 detects the drop in ER 
calcium concentration and translocates to the plasma membrane-ER junction where it binds 
to the calcium channel Orai1. To deplete HEK cells of intracellular calcium stores, the cells 
were treated with thapsigargin in calcium free media. Subsequently, calcium was added to 
the media and intracellular calcium concentration was measured. This technique effectively 
measures the degree of SOCE. It was found that in HEK cells transfected with S1R, the 
increase in intracellular calcium subsequent to addition of calcium to the media was blunted 
compared to cells not expressing S1R. A similar effect was observed in cells treated with 
carbachol and ATP (these compounds trigger endogenous depletion of ER calcium). To 
investigate whether ligands of S1R can modulate the S1R-mediated effects on SOCE, cells 
were treated with the S1R agonist SKF10047 and the S1R antagonist BD-1047. It was 
observed that the antagonist enhanced SOCE while the agonist inhibited SOCE in HEK 
and CHO cells transfected with S1R. Coimmunoprecipitation assays revealed that S1R 
associates with STIM1 and that treatment with a S1R agonist increases this association 
while treatment with a S1R antagonist decreases it. Upon calcium depletion, the STIM1-
S1R complex translocates to the ER-plasma membrane interface, where it associates with 
Orai1. The sigma-1 receptor decreases the speed at which this translocation occurs and 
additionally inhibits association with Orai1. It was determined that the S1R exerts its 
effects via STIM1 rather than via association with Orai1 (Srivats et al., 2016). 
2.4.4 Sigma-1 Receptor and the Actin Cytoskeleton 
 Following the finding that sigma-1 receptor activation mediates dissociation of 
IP3R3 from ankyrin (Hayashi and Su, 2001), it was proposed that cocaine may mediate 
changes to the spectrin-actin cytoskeleton via the sigma-1 receptor (Su and Hayashi, 2000). 
Ankyrin is an adaptor protein that is normally bound to the spectrin component of the actin-
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spectrin cytoskeleton. Specifically, spectrin serves as a crosslinker between actin filaments, 
forming the mesh that gives the plasma membrane definition. Ankyrin, as an adaptor 
protein, connects spectrin to other membrane proteins and cell adhesion molecules. This 
dissociation results in increased flux of calcium ions from the ER due to enhanced binding 
of IP3 to IP3R3. The dissociation mediated by cocaine as a ligand has been observed to be 
persistent for up to two hours, suggesting this dissociation may not be transient in nature. 
Calcium can modulate the interaction between spectrin and actin (Tanaka et al., 1991). 
Hayashi and Su also proposed that cocaine-mediated modulation of intracellular calcium 
due to activation of Gq-coupled D1x receptors may also modulate the cytoskeleton. It was 
specifically proposed that these changes in the cytoskeleton can affect the architecture of 
dendrites and dendritic spines, but it may be equally plausible that these same changes 
occur in astrocytes. 
 
2.5 Distribution of the Sigma-1 Receptor in the Rat NAcc and PrL 
2.5.1 Background 
 The sigma-1 receptor is expressed in many tissues including the brain, heart, lungs, 
and liver. It is well known that neurons express the sigma-1 receptor. Previous 
immunohistochemical data suggests that the S1R is moderately expressed by neurons and 
ependymocytes throughout the brain, including the striatum. However, in this report, there 
was no sigma-1 receptor staining within astrocytes (Alonso et al., 2000). In this report, 
sigma-1 immunoreactivity detected via electron microscope was punctate and located in 
the perikaryal and dendrites of neurons, with a distinct absence of any immunoreactivity 
in the axons. Nevertheless, more recent data has come to light suggesting that both neurons 
and astrocytes in the striatum express the sigma-1 receptor modestly (Francardo et al., 
2014). If indeed the sigma-1 receptor is expressed in astrocytes, then it is plausible that 
sigma-1 receptor agonists can promote morphological alterations by its interactions with 
the actin cytoskeleton and IP3R (Hayashi and Su, 2001). Indeed, in vitro and in vivo 
treatment with METH in mice increases astrocyte reactivity (indicated by stellation and 
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increased GFAP expression). Moreover, addition of METH to astrocyte-neuron cell 
cultures enhanced intracellular calcium release evoked by glutamate and dopamine (Narita 
et al., 2005). Whether these METH-mediated alterations are dopamine-mediated, S1R-
mediated, or both is still an open question in the field.  
 In order for the S1R to be relevant to astrocytic physiology, it must be expressed 
by astrocytes. Given the conflicting literature regarding expression of S1R by astrocytes, 
the present experiment was designed to probe the expression of the S1R by astrocytes. The 
prelimbic cortex and the nucleus accumbens were selected due to their involvement in 
mediating drug-seeking behavior. 
2.5.2 Materials and Methods 
 Male Sprague-Dawley rats weighing between 322 and 566 grams were deeply 
anesthetized using ketamine/xylazine/acepromazine and transcardially perfused first with 
cold 4% paraformaldehyde (PFA) and cold 1X phosphate-buffered saline (PBS). The 
brains were removed and 1 mm thick sections were cut on the vibratome (Leica VT1200) 
containing the PFC and nucleus accumbens in 1X PBS. The thick sections were 
cryoprotected for two days in 30% sucrose (prepared in 1X PBS). They were then frozen 
on the cryostat at -16oC and sliced into 50 µm thick sections. The 50 µm thick slices were 
placed into a freezer storage medium consisting of the following: 30% w/v sucrose in a 
solution containing 300 mL of ethylene glycol, 300 mL of glycerol, and 300 mL of 1X 
PBS. 
 The 50 µm sections were thawed at 4 degrees Celsius, placed in 15% sucrose (in 
1X PBS) for 15 minutes, and then washed in 1X PBS three times for 10 minutes. Two 
different primary antibody cocktails were used, one containing 1:1000 rabbit anti-Sigma1 
receptor (Abcam, ab53852) and 1:1000 goat anti-GFAP (Abcam, ab53554) while the other 
contained 1:1000 mouse anti-NeuN (Novus Biologicals, NBP1-92693) and 1:1000 rabbit 
anti-Sigma1 receptor. These two different groups are called Group GSD (GFAP, Sigma-1, 
and DAPI) and NS (NeuN and Sigma-1). Both were prepared in an antibody dilution buffer 
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containing 3% normal donkey serum in 1X PBS with 0.2% Triton X-100. First, the slices 
were blocked in a solution of 10% v/v normal donkey serum and 0.2% Triton X-100 in 1X 
PBS for 30 minutes. Subsequently, the primary antibody cocktail was added, and the slices 
were allowed to incubate overnight at 4 degrees Celsius. After overnight incubation, the 
slices were washed 3x10 minutes in 1X PBS and blocked again using a blocking buffer 
serum from the same animal as the host identity of the subsequent secondary antibody. For 
slices stained with anti-NeuN, normal goat serum was used while for slices stained with 
anti-GFAP, normal donkey serum was used. Donkey anti-goat A647 (Abcam, ab150135), 
goat anti-rabbit or goat anti-mouse A405 (Thermo-Fisher, A31553) were used. Slices were 
incubated with each secondary antibody for 2 hours at room temperature. After washing 
3x10 minutes, the slices were blocked with normal goat serum-containing blocking buffer 
and incubated with goat anti-rabbit A594 (Abcam, ab150088) for 2 hours at room 
temperature. Slices stained with GFAP were incubated with 2.86 µM DAPI for 10 minutes 
and then washed 3x10 minutes with 1X PBS-T (0.2% Triton X-100 in 1X PBS). Slices 
strained with NeuN were washed 3x10 minutes with 1X PBS. All slices were then mounted 
and coverslipped using Prolong Gold Antifade or Prolong Diamond Antifade. 
 For image acquisition, the Nikon A1R confocal microscope was used. The pinhole 
diameter was set at 1.2 AU for all samples. The general region of interest (prelimbic cortex 
or nucleus accumbens) was identified using the 10x (air-immersion) and 20x (water-
immersion) objectives. Initial gain and power settings for each channel are displayed in 
Table 2.1. At all times, the gain was 30x higher than the power of the laser. Images were 
taken with 4x line averaging at resolution 1024x1024. First a large tiled image was taken 
using the 40x objective, then the area of interest was identified and a z-stack with slices 
spaced 1 µm apart (ranging from 10-12 µm total per stack) was taken. The resulting ND2 
files were saved and imported to NIS-Elements for processing. Background was subtracted 
using the rolling ball method and images were deconvolved for 10 iterations using the blind 
method of 3D deconvolution. After image acquisition, all slices were visualized using the 
10x bright field objective on the AxioScan slide scanner. Slices that did not contain the 
nucleus accumbens or the prelimbic cortex were excluded from analysis. 
 
47 
 
   Table 2.1 The initial gain and power settings utilized to visualize immunostained tissue 
 HV (gain) Power 
647 nm 90 3 
561 nm 90 3 
405 nm 150 5 
 
 Data analysis was conducted using Fiji ImageJ. First, either DAPI-positive or 
NeuN-positive cells were counted using the multi-point tool. For tissue stained with anti-
GFAP, subsequently, all astrocytes with visible nuclei were counted. The criterion for 
inclusion as an astrocyte were: GFAP immunoreactivity must fully or partially surround 
the DAPI staining and the identified cells must have two or more visible processes 
projecting from them. The criteria for identification as a neuron was simply round NeuN 
immunoreactivity. For a cell to be considered positive for the sigma-1 receptor, 3 or more 
puncta had to be present within the GFAP/DAPI+ or NeuN+ area. Statistical analysis (two 
sample t-tests assuming unequal variance) was conducted in GraphPad Prism. Total cell 
count was calculated by counting all cells in a z-stack and dividing by the volume enclosed 
by the z-stack. Proportions were calculated by dividing one category in the total cell count 
by another. 
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2.5.3  Results 
 
Figure 2.5 A maximum intensity projection of a NAcc slice; GFAP (magenta), Sigma1 
receptor (yellow), and DAPI (blue). Z-stack thickness: 11 µm. 
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Figure 2.6 A maximum intensity projection of a NAcc slice; NeuN (blue) and Sigma1 
(yellow) 
 For total cell count analysis of NAcc slices in group NS there were n = 10 slices 
and n = 7 in group GSD included in the analysis. For analysis of PrL slices, in group NS, 
there were n = 6 slices and in group GSD, there were n = 6 slices. These slices came from 
two animals. The total cell count revealed a significantly greater density of DAPI-positive 
cells in the nucleus accumbens versus the prelimbic cortex (p < 0.05) and a significantly 
greater density of DAPI-stained cells with sigma-1 receptor immunoreactivity (group 
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GSD; p < 0.05) in the nucleus accumbens versus the prelimbic cortex. All total count data 
is presented in Figure 2.7. Astrocytes in both the nucleus accumbens and prelimbic cortex 
possessed characteristic sigma-1 receptor immunoreactivity in their processes (Figure 2.9). 
In NS slices, sigma-1 receptor immunoreactivity was distributed throughout the cytosol 
and on the plasma membrane of neuronal cell bodies (Figure 2.10). No significant 
differences between regions were found when analyzing the proportion of cells that were 
sigma-1 receptor immunoreactive (Figure 2.8). In both the PrL and the NAcc, 
approximately 73% of DAPI stained nuclei contained clustered puncta of sigma-1 receptor 
immunoreactivity. Interestingly, on average, almost all (97.8%) neurons in both regions 
expressed the sigma-1 receptor, while most, but not all (91.2%) GFAP-positive astrocytes 
expressed the sigma-1 receptor. 
 
Figure 2.7  A graph showing the total cell counts. Note that the Sigma+ category denotes 
sigma-1 receptor-positive cells in GSD slices while Sigma+ (NeuN) denotes cells in NS 
slices 
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Figure 2.8 A graph showing proportions. Here, the proportion represents the number of 
cells positive for type A (i.e. sigma-1 receptor immunoreactivity) out of cells positive for 
type B (i.e. DAPI+ cells). No statistically significant differences were noted between 
regions. 
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Figure 2.9 A maximum-intensity projection image of a single astrocyte in the nucleus 
accumbens taken with the 60x oil-immersion objective. Note both perinuclear (blue 
indicates DAPI) and peripheral sigma-1 receptor immunoreactivity (yellow) in the 
astrocyte (magenta) or on the membrane of its processes. 
 
Figure 2.10 A maximum-intensity projection image of a neuron (blue is NeuN 
immunoreactivity) in the nucleus accumbens with sigma-1 receptor immunoreactivity 
(yellow) inside the cytosol/nucleus and along the surface of the cell body. Image taken 
with the 40x water-immersion objective. 
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2.5.4  Discussion 
 In conclusion, we note that like Francardo and coworkers, there is detectable and 
significant sigma-1 receptor density in astrocytes of the striatum, particularly in the nucleus 
accumbens. It is possible that the antibody prepared by Alonso and coworkers (Alonso et 
al., 2000) does not bind the sigma-1 receptor with high enough avidity (the total binding 
strength at every binding site on the antibody) or affinity to detect the levels of expression 
within striatal astrocytes. Indeed, they reported low to medium-intensity sigma-1 receptor 
immunoreactivity in the striatum, in stark contrasts with results that we and others have 
found (Francardo et al., 2014). It may also be possible that the use of a confocal microscope 
by ourselves and Francardo et al. permitted greater resolution than the images obtained by 
Alonso and coworkers.  The source of this discrepancy remains unknown. Nevertheless, 
here, we demonstrate conclusively that astrocytes in the nucleus accumbens and the 
prelimbic cortex express the sigma-1 receptor. 
 The increased DAPI+ cell count in the nucleus accumbens versus the prelimbic 
cortex suggests a greater cell density in the nucleus accumbens. The greater number of 
sigma-1 receptor immunoreactive cells in the nucleus accumbens and prelimbic cortex 
versus the number of astrocytes counted suggests that many other cells (including 
astrocytes that do not express GFAP) also express the sigma-1 receptor. The increased total 
cell count of sigma-1 receptor immunoreactive DAPI-positive cells is not reflected in the 
analysis of the proportion of sigma-1 positive cells, suggesting that the increased total 
sigma-1 immunoreactive DAPI-positive cell count may simply be a product of increased 
cell density in the nucleus accumbens. However, it should be noted that GFAP expression 
is highly heterogeneous and that striatal astrocytes typically express less GFAP mRNA 
relative to hippocampal astrocytes (Chai et al., 2017). Thus, it is plausible that a subset of 
the DAPI-positive, S1R-positive cells are really astrocytes that do not express GFAP.  
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 There are several limitations to this experiment. First is the fact that the number of 
channels on the Nikon A1R in confocal mode limits the number of different antibodies that 
can be used on a single slice. Ideally, both NeuN and GFAP would be labelled in the slices 
in addition to the Sigma-1 receptor, and the nuclei of NeuN and GFAP-positive cells would 
also be visible. However, this could not be accomplished due to the limited number of 
channels on the confocal microscope. While it is theoretically plausible to use the goat anti-
mouse A405 antibody in conjunction with the donkey anti-goat A647 and goat anti-rabbit 
A594 antibody, this would have meant that DAPI could not be used. Detection of cell 
nuclei is important for counting astrocytes, as their convoluted morphology makes it 
difficult to distinguish one astrocyte from the other. Second, the small sample size limits 
statistical analysis because it is not possible to account for potential animal to animal 
differences: only two rats were sacrificed to generate these slices. In order to determine the 
influence of animal-to-animal variability on these results, a larger number of animals and 
a larger number of sections should have been used. 
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CHAPTER 3. SIGMA-1 RECEPTOR-MEDIATED EFFECTS OF 
METHAMPHETAMINE IN ACUTE STRIATAL SLICE PREPARATIONS FROM THE 
RAT 
3.1 Background 
 From the previous experiment, we have concluded that there is robust expression 
of the sigma-1 receptor in both astrocytes and neurons of the nucleus accumbens. The 
sigma-1 receptor is involved in mediating dopamine release in the mouse nucleus 
accumbens slice preparations. An indirect link between reactive oxygen species (ROS) via 
the sigma-1 receptor is suggested to contribute to dopamine release because both 
METH+BD-1063 and the antioxidant TEMPOL+METH reduced dopamine efflux relative 
to METH alone. It was found that VMAT2 was S-glutathionylated and that this S-
glutathionylation can be blocked by incubation with the sigma-1 receptor antagonist BD-
1063 (Hedges et al., 2018). Glutathionylation impairs VMAT2 function and thus enhances 
accumulation of dopamine in the cytosol. Although there is evidence of VMAT2 
expression in astrocytes (Petrelli et al., 2018), generation of reactive oxygen species (ROS) 
and increased intracellular calcium release via the sigma-1 receptor activation by METH 
could have different effects on astrocytes than on neurons. It has already been described in 
the literature that extracellular dopamine modulates astrocyte morphology in a 
concentration-dependent manner (Galloway et al., 2018). Therefore, it is plausible that 
elevated dopamine release via the sigma-1 receptor can induce morphological alterations 
in astrocytes. 
Since the sigma-1 receptor modulates the actin-spectrin cytoskeleton (Su and 
Hayashi, 2001) and intracellular calcium release enhanced by the actions of sigma-1 
receptor could potentially affect the interaction between spectrin and actin (Tanaka et al., 
1991), it is also plausible that direct activation of the sigma-1 receptor can modulate the 
morphology of astrocytes by directly altering the actin-spectrin cytoskeleton. 
 In the present experiment, we sought to determine the contribution of the sigma-1 
receptor to changes in sigma-1 receptor distribution and astrocytic morphology. Although 
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we could not probe the effects of dopamine receptor activation, we were able to do so 
indirectly, as treatment with BD-1063 (Hedges et al., 2018) and PRE-084 (Sambo et al., 
2017) have been shown to reduce dopamine release in slice preparation and dopamine 
neuron cell culture, respectively. 
 3.2 Materials and Methods 
 Two adult male Sprague-Dawley rats were deeply anesthetized with isoflurane and 
then decapitated. The brain was sectioned into 300 µm thick slices containing the striatum, 
particularly the nucleus accumbens as well as the caudate-putamen. Slices were incubated 
in aCSF (in mM: 2 CaCl2, 3 KCl, 1 MgCl2, NaH2PO4 1.25, NaHCO3 26, and d-glucose 10) 
until all necessary slices were cut. The slices were transferred to solutions according to 
Table 3.1; all solutions were prepared in aCSF. The concentration of PRE-084 used was 
derived from Sambo et al., 2017. The concentration for BD-1063 was taken to be a 
saturating concentration from Zhang et al., 2017. The concentration of METH used was 
calculated from results indicating the physiological mass of methamphetamine per unit 
mass of brain tissue derived from experiments in which rats were given 1 mg/kg of 
methamphetamine (i.v., Riviére et al., 2000). The slices were incubated for 2 hours at 37 
°C before they were removed and placed in 4% paraformaldehyde in 1X PBS. After 3 hours 
of fixation, the slices were transferred to 30% sucrose in 1X PBS for cryoprotection and 
allowed to cryoprotect until the slices sank in the medium. 
Table 3.1 All solutions used to incubate the slices from two different animals 
  
Meth (24.7 μM) 
 
aCSF 
BD-1063 (49.5 μM) 300 μm  (n = 3 slices) Not collected 
PRE-084 (9.9 μM) 300 μm (n = 1 slice) 300 μm (n = 1 slices) 
aCSF 300 μm (n = 1 slice) 300 μm (n = 1 slices) 
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 From the 300 µm slices, 50 µm thick sections were cut on a cryostat (Leica CM 
1860) and placed into freezer storage medium. When IHC was conducted, the sections 
were thawed at 4 ºC and then transferred to 15% sucrose solution. The slices were then 
transferred to 1X PBS and washed 3x10 minutes. They were then blocked in  blocking 
buffer (10% NDS and 0.2% Triton X-100 in 1X PBS) and then incubated with primary 
antibody cocktail [1:1000 polyclonal rabbit anti-Sigma1 (Abcam, ab53852)  and 1:1000 
polyclonal goat anti-GFAP (Abcam, ab53554) in 3% NDS, 0.2% TX-100, and 1X-PBS] 
overnight at 4 ºC. 
 After incubation with the primary antibodies, the slices were washed 3x10 minutes 
with 1X PBS at room temperature. They were then blocked in blocking buffer made from 
NGS rather than NDS for 30 minutes. After protecting the slices from light and removing 
the blocking buffer, 1:400 polyclonal goat anti-rabbit A594 (buffer composition: 3% NGS 
and 0.2% Triton X-100 in 1X PBS; Abcam, ab150088) was added and the slices were 
incubated for 2 hours at room temperature. Subsequently, the slices were washed 3x10 
minutes with 1X PBS and blocked again with blocking buffer made from NDS. The slices 
were incubated with 1:400 polyclonal donkey anti-goat A647 (Abcam, ab150135) for 2 
hours. They were then washed 3x10 minutes with 1X PBS and transferred to DAPI working 
solution (2.86 µM DAPI in PBS-T consisting of 0.2% TX-100 in 1X PBS). Following 
incubation for 10 minutes, the slices were washed 3x10 minutes in PBS-T. They were then 
mounted and coverslipped with Prolong Diamond Antifade. 
 All images were acquired on the Nikon A1R confocal microscope with a pinhole 
diameter of 1.2 AU and image resolution of 1024x1024 using a 60x oil-immersion 
objective (NA: 1.4) with 4x line averaging. The power of the laser and the gain was set 
such that gain was always 30x greater than the power (initial settings were identical to 
those displayed in table 2.1). Since some slices contained the nucleus accumbens and others 
did not, the images are of areas within the caudate putamen. Large, stitched images of all 
the slices can be seen in Figure 3.1 while maximum intensity projection images can be seen 
in Figure 3.2. 
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Figure 3.1 Large stitched images of striatal tissue; DAPI (blue), anti-Sigma1 receptor 
(yellow), and anti-GFAP (purple). Top left: aCSF; top middle: METH; top right: METH 
+ BD-1063; bottom left: METH + PRE; bottom right: PRE 
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Figure 3.2 Representative images showing the maximum intensity projection of each 
slice (z-projection was taken of 6 slices or 6 µm containing the most astrocytes, hence the 
differences in background); DAPI (blue), anti-Sigma1 receptor (yellow), and anti-GFAP 
(purple). Top left: aCSF; top middle: METH; top right: METH + BD-1063; bottom left: 
METH + PRE; bottom right: PRE 
 For analysis of sigma-1 receptor puncta, first all DAPI and GFAP+ cells were 
counted in each slice using Fiji ImageJ. Analysis was conducted on slices such that the 
sample size was at least 15 astrocytes per group. The number of sigma-1 receptor puncta 
within each cell was counted. Any puncta on or adjacent to the DAPI-stained nucleus was 
categorized perinuclear while puncta in the processes were categorized as peripheral. An 
example of the puncta counting Only puncta within the DAPI+ or GFAP+ area were 
counted. For reconstruction of astrocytes, Bitplane Imaris 9.6 was used to generate a 
surface for 5 cells per slice. For all cells, only the largest continuous surface encircling the 
nucleus was considered to limit inclusion of processes from other astrocytes. Processes 
were counted using the 3D reconstruction of each cell and only processes extending from 
the cell body of an astrocyte were counted.  
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 The (+)-methamphetamine hydrochloride was purchased from Cayman Chemical 
(#13997), PRE-084 from Sigma-Aldrich (P2607), and BD-1063 from Tocris (#0883). The 
composition of the cutting solution was, in mM: 2 CaCl2, 3 KCl, 1 MgCl2, NaH2PO4 1.25, 
NaHCO3 26, d-glucose 10, sucrose 219. All reagents were used without further 
purification. 
All statistics were calculated in GraphPad Prism 8.4.3. To assess homogeneity of 
variance, Bartlett’s test and the Brown-Forsythe test were used. Based on the results from 
the tests for differences in variance, homogeneity of variance could be assumed for all 
analyses. Normal one-way ANOVA for the stellation count and the surface area to volume 
ratio where therefore used and normal two-way ANOVA was used for the puncta 
localization count. The method of Tukey was used to calculate adjusted p-values for 
multiple comparisons for all data. Error bars in all the graphs show SEM. 
 
3.3 Results 
 The volume and cell surface area data were imported from Imaris. The ratio of 
surface area to volume has previously been used as a metric for astrocyte complexity in 
astrocytes virally transfected with AAV5 GfaABC1D-Lck-GFP (Testen et al., 2018). Since 
the fine astrocytic processes contribute to greater surface area than volume, increased 
surface area:volume ratio indicates an increase in these fine processes which in turn 
indicates astrocytic complexity. Here, the surface area:volume ratio is used similarly, but 
on anti-GFAP stained brain slices. One-way ANOVA revealed no significant difference 
was found between treatment groups on the surface area:volume ratio [F4, 29 = 0.9317; p > 
0.05], suggesting that this metric may not be effective for analysis of GFAP-stained images 
(Figure 3.3. It is also plausible that the length of time for incubation of slices with drugs 
may have not been sufficient to evoke dramatic remodeling of the astrocytic cytoskeleton. 
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Figure 3.3 The surface area:volume ratio. Astrocytes were reconstructed on Imaris and 
the surface area and volume parameters were measured. There was no significant 
difference between groups (n=14 cells for BD+METH; n=5 cells for all other groups)  
 
 Astrocyte stellation was analyzed as the number of primary processes (stellations) 
were counted in Imaris by locating the nucleus and counting the number of GFAP+ 
processes extending radially from the nucleus (Figure 3.4) since the nucleus is contained 
by the cell body of astrocytes. Note that astrocytes in vivo are typically already stellate 
while astrocytes grown in culture are not usually stellate unless certain drugs are added to 
the media. One-way ANOVA revealed a significant difference between groups [p < 0.05; 
F(4, 29) = 3.913]. The method of Tukey revealed a significant difference between the METH 
and the aCSF group (p < 0.05), with the METH astrocytes possessing a greater stellation 
count. Treatment of METH slices with the S1R antagonist, BD-1063, abolished the 
increase in stellation count (p < 0.05). However, treatment with the S1R agonist, PRE-084, 
alone did not alter the ramification count relative to the aCSF control. The combination of 
METH and PRE-084 reduced the ramification count relative to METH alone, but this result 
did not reach statistical significance. 
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Figure 3.4 The stellation counts on reconstructed astrocytes. In addition to the significant 
difference between METH and aCSF, there was a significant difference (p < 0.05) 
between METH and METH + BD-1063 as well as a significant difference between PRE 
and METH (p < 0.05) revealed by multiple comparisons analysis.  
  
 Next, to assess whether the drug treatments altered the intracellular distribution of 
the sigma-1 receptor, sigma-1 receptor immunostained puncta were counted (Figure 3.5). 
Specifically, puncta within the nucleus or adjacent to the nucleus were counted as 
perinuclear while puncta in GFAP+ territory were counted as peripheral. Note that this type 
of analysis is not quantitative and that very bright clusters of puncta were counted as a 
single punctum. In all treatment groups, most astrocytes possessed both peripheral and 
perinuclear puncta, suggesting that in astrocytes, the sigma-1 receptor may be more widely 
distributed throughout the cell in basal state compared to neurons. A two-way ANOVA 
revealed significant main effects of treatment and localization [Treatment: F(4, 214) = 
7.008, p < 0.0001; Localization: F(1, 214) = 59.70, p < 0.0001] as well as a significant 
interaction effect [F(4, 214) = 6.148, p < 0.005]. Using the method of Tukey for multiple 
comparisons revealed no significant difference between groups for perinuclear puncta. 
However, there was a statistically significant (p < 0.05) increase in peripheral puncta for 
METH-treated slices versus aCSF-treated slices. This increase was abolished by addition 
of BD-1063 (p < 0.0001) and PRE-084 (p < 0.001). Contrary to observations in striatal 
neurons (Francardo et al., 2014), PRE-084 did not induce redistribution of the sigma-1 
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receptor relative to aCSF. In fact, in all samples, there were several puncta located in the 
processes of astrocytes, far from the nucleus. Curiously, when compared to the slice 
incubated with METH and PRE-084, the slice incubated in PRE-084 alone demonstrated 
markedly increased peripheral puncta (p < 0.005). Thus, both BD-1063 and PRE-084 
abolished the effect of METH on intracellular distribution of the sigma-1 receptor.
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Figure 3.5 The puncta count data. No significant difference was found among treatment 
groups for perinuclear localization of the sigma-1 receptor.  
 
 
3.4 Discussion 
 Methamphetamine administration has been shown to increase GFAP and sigma-1 
receptor immunoreactivity (Zhang et al., 2015) in a manner that can be blocked by 
treatment with the sigma-1 receptor antagonist BD-1047. Here, we provide preliminary 
evidence that blockade of the sigma-1 receptor can also attenuate methamphetamine-
induced increase in the stellation of astrocytes as well as the redistribution of sigma-1 
receptors to the processes. Given that treatment of slices with PRE-084 alone did not induce 
an increase in stellation, it is likely that sigma-1 receptor activation is not sufficient to 
induce stellation. It is plausible that dopamine at dopamine receptors rather than 
methamphetamine at sigma-1 receptors initiates the morphological alterations. A study in 
astrocyte cell culture found that dopamine can induce rapid morphological and 
transcriptomic alterations via PARP1 activation of CTCF in a manner that can be blocked 
by D1 and D2 receptor antagonists (Galloway et al., 2018). However, in the case of 
methamphetamine, the present data suggests that the sigma-1 receptor is involved 
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somewhere in the pathway from dopamine receptor activation to morphological changes. 
The sigma-1 receptor may modulate signaling via dopamine receptors at several points 
along the signal transduction cascade. Since activation of the sigma-1 receptor can increase 
the affinity of IP3 for IP3R3, it is possible that binding of methamphetamine to the sigma-
1 receptor and increased binding of dopamine to the phospholipase C-stimulating D1x 
receptor can potentiate calcium release from the ER and sigma-1 receptor activation can 
induce dissociation of IP3R3 from ankyrin and the sigma-1 receptor which could alter the 
cellular cytoskeleton (Su and Hayashi, 2001). These experiments do not allow for the 
preclusion of direct sigma-1 receptor interaction with the D1x receptor. It has been 
demonstrated that the sigma-1 receptor can potentiate cAMP accumulation mediated by 
the canonical Gs-coupled D1 receptor (Navarro et al., 2010). Thus, since the sigma-1 
receptor forms oligomeric complexes with D1 receptors and also potentiates Gs-mediated 
signaling at the D1 receptor (Fu et al., 2010), it is also plausible that the sigma-1 receptor 
may act similarly with phospholipase C-stimulating dopamine receptors (D1x). See Figure 
3.6 for a summary of hypothesized mechanisms by which methamphetamine can induce 
alterations in astrocytic physiology. 
 The surprising observation that PRE-084 attenuated redistribution of the sigma-1 
receptor in slices also treated with METH may be a product of two phenomena: that PRE-
084 attenuates METH-mediated dopamine release from neurons (Sambo et al., 2017) and 
that dopamine mediates increased stellation and therefore increased cross-sectional area. 
Since the technique employed in the present experiment utilized a manual count of the 
individual puncta regardless of intensity or size, it is plausible that an increased density of 
puncta in the METH+PRE condition made it difficult to discretize individual puncta. 
Instead of forming discrete puncta, a “lawn” of sigma-1 receptor immunoreactivity was 
observed. A simpler explanation is that PRE-084 is more potent at promoting the lower-
order oligomeric states of the S1R, resulting in finer, more distributed puncta. This 
speculation is corroborated by findings suggesting that PRE-084 alone induces the 
formation of lower-order oligomers (Schmidt et al., 2018); This would mean, presumably, 
that finer puncta would be detected more easily than dense, bright puncta that may overlap 
and form intense clusters rather than discrete puncta. The converse may be true of the 
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M+BD condition; if BD-1063 induces the formation of higher order oligomers, clusters of 
sigma-1 receptor would appear to form fewer but brighter puncta.  
 There were several limitations to the present work. First, utilizing the same dilution 
of anti-GFAP antibody as was used in the previous experiment was not suitable for this 
experiment, in which excessive GFAP-positive staining impaired identification of 
individual astrocytes for 3D reconstruction. The small sample size limits the statistical 
power of the stellation count, since only five astrocytes per slice could be identified for 
morphological analysis in Imaris due to time limitations; future experiments should employ 
either thicker striatal slices for IHC or a larger cohort of animals. Moreover, it is unclear 
why the METH + PRE slice exhibited the marked decrease in peripheral sigma-1 receptor 
puncta. Lastly, in order to maximize the use of the slices, the entire striatum, the dorsal 
striatum was selected for analysis. It is possible that there may be regional differences in 
sigma-1 receptor expression. Indeed, differences have been observed in 
immunocytochemical studies assessing regional expression of the sigma-1 receptor. For 
example, Alonso and coworkers reported mild sigma-1 receptor immunoreactivity in the 
caudate/putamen but moderate sigma-1 receptor immunoreactivity in the nucleus 
accumbens (Alonso et al., 2000). Here, the striatum was treated as a whole and locations 
throughout the striatum were selected. 
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Figure 3.6 In the absence of sigma-1 receptor ligand, the sigma-1 receptor forms a 
complex between ankyrin, IP3R3, and the spectrin/actin cytoskeleton. In the presence of 
METH (black circles), the IP3R3 dissociates from ankyrin-spectrin which in turn 
potentiates IP3 (green circles) binding to IP3R3. This would shift the dose-response curve 
between calcium efflux and [IP3] to the left, resulting in enhanced calcium efflux from 
the ER, particularly in the presence of phospholipase C signaling mediated by the D1x 
receptor. Binding of agonists to the sigma-1 receptor promotes lower order oligomeric 
states and dissociation from BiP. These lower order oligomeric states can translocate to 
the plasma membrane and interact with D1. Whether the resulting complexes exhibit 
enhanced coupling between receptor and G-proteins remains an open question 
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3.5 Future Directions 
 While these data provide preliminary evidence for the role of the sigma-1 receptor 
in methamphetamine-mediated alterations to astrocyte physiology in the dorsal striatum, it 
is unclear whether these alterations also occur in the ventral striatum. One report suggests 
that there is no change to the GFAP-positive processes immediately following self-
administration of methamphetamine in the nucleus accumbens (Siemsen et al., 2019), 
however there are noted differences in astrocyte morphology after self-administered and 
experimenter administered methamphetamine (Narita et al., 2005). Thus, in order to clarify 
whether the changes to astrocyte morphology and sigma-1 receptor distribution occur in 
the ventral striatum, these experiments should be repeated in slices containing the nucleus 
accumbens. Moreover, given the morphological differences in astrocytes noted between 
methamphetamine self-administration and experimenter-administered methamphetamine, 
both methods of methamphetamine administration should be compared for effects on 
redistribution of the sigma-1 receptor. 
 Given that GFAP is not expressed in the fine astrocytic processes that constitute 
the majority of the surface area of astrocytes, utilization of both GFAP 
immunohistochemistry and virally-transfected astrocyte-specific fluorescent proteins may 
reveal details that could not be uncovered using the present method. For example, it is 
unknown whether the sigma-1 receptor can be found in the fine, GFAP-negative processes 
of astrocytes. If they can, then the puncta count data may represent an underestimate. Given 
that a manual count of sigma-1 receptor puncta in anti-Sigma1 immunostained tissue is not 
representative of the total expression of the sigma-1 receptor or the oligomeric status of the 
sigma-1 receptor (due to the nature of antibody binding to proteins and the diffraction limit 
of light microscopy), molecular approaches such as BRET would be more suited to 
investigate the precise oligomeric status of sigma-1 receptors and more quantitative 
approaches such as RT-qPCR could be used in future work to address the limitations of 
optical methods such as immunohistochemistry in the context of determining total sigma-
1 receptor expression. 
 It is also noted that the present experiments cannot distinguish efficiently between 
dopamine-mediated changes to astrocytic morphology and sigma-1 receptor-mediated 
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changes to astrocytic morphology. Although PRE blocked METH-induced increases in 
stellation, it is not clear whether this decreased stellation occurs due to decreased dopamine 
release from neurons (Sambo et al., 2017) or direct action on sigma-1 receptors within 
astrocytes. A potential future experiment could entail incubating striatal slices from three 
different types of animals (wild-type, complete sigma-1 receptor knockout, and only 
expressing sigma-1 receptor in GFAP-positive astrocytes) and assessing the changes in 
morphology. A perhaps even simpler means of assessing the contribution of dopamine 
versus the sigma-1 receptor would be to conduct the present experiments in primary 
astrocyte culture. Since cultured astrocytes lack dopamine, it would be relatively 
straightforward to dissociate the effects of dopamine on astrocytic morphology and the 
effects of sigma-1 receptor activation on astrocytic morphology. From work in our lab, it 
has been observed that addition of cocaine alone to the culture medium can induce rapid 
stellation of astrocytes (Ortinski, unpublished observations), thus it is plausible that factors 
other than dopamine, particularly the sigma-1 receptor, can contribute to alterations in 
astrocytic morphology. 
 The sigma-1 receptor is a regulator of intracellular calcium dynamics (Hayashi et 
al., 2000; Sambo et al., 2017). Many of the initial experiments (Hayashi et  al., 2000; 
Hayashi and Su, 2001; Hayashi and Su, 2007) exploring the molecular mechanisms of 
sigma-1 receptor-mediated alterations in intracellular calcium utilized the NG108 cell line, 
a hybrid between glioma cells (cancerous astrocytes) and neuroblastoma cells (cancerous 
neuronal progenitor cells), or Chinese hamster ovarian cells. While monocultures of cells 
are a valuable tool to study events on the molecular level, results obtained from 
experiments using monocultures must be considered with a grain of salt, as it is not always 
possible to extrapolate events that occur in culture to the situation in a living organism. For 
example, it is difficult to determine whether increased dopamine or sigma-1 receptor 
binding due to methamphetamine treatment are responsible for the alterations to astrocytic 
physiology. Viral transfection of astrocytes in vivo with Lck-GCaMP expressed under the 
GFAP promoter is a sensitive means of detecting intracellular calcium oscillations 
throughout the entire astrocyte (Shigetomi et al., 2013). A potential future experiment 
could involve incubating striatal brain slices in baths containing the treatment drugs in the 
present experiment and observing the effects on intracellular calcium dynamics. Addition 
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of selective D1 receptor antagonists to the bath could be a means of observing the 
contribution of signaling via the phospholipase C-stimulating D1x receptor.  
 
 
71 
 
BIBLIOGRAPHY 
 
SAMHSA, (2017). Results from the 2016 National Survey on Drug Use and Health: 
Detailed Tables. NSDUH H-52. Rockville, MD. 
  
Ablordeppey, S. Y., et al. (2000). "Is a nitrogen atom an important pharmacophoric 
element in sigma ligand binding?" Bioorganic & Medicinal Chemistry 8(8): 2105-2111. 
 
Aguinaga, D., et al. (2018). "Cocaine Effects on Dopaminergic Transmission Depend on 
a Balance between Sigma-1 and Sigma-2 Receptor Expression." Frontiers in Molecular 
Neuroscience 11. 
 
Agulhon, C., et al. (2008). "What Is the Role of Astrocyte Calcium in Neurophysiology?" 
Neuron 59(6): 932-946. 
 
Alonso, G., et al. (2000). "Immunocytochemical localization of the sigma1 receptor in the 
adult rat central nervous system." Neuroscience 97(1): 155-170. 
 
Anderson, C. M. and R. A. Swanson (2000). "Astrocyte glutamate transport: Review of 
properties, regulation, and physiological functions." Glia 32(1): 1-14. 
 
Aydar, E., et al. (2002). "The Sigma Receptor as a Ligand-Regulated Auxiliary 
Potassium Channel Subunit." Neuron 34(3): 399-410. 
  
Baker, D. A., et al. (2003). "Neuroadaptations in cystine-glutamate exchange underlie 
cocaine relapse." Nature Neuroscience 6(7): 743-749. 
 
Bergersen, L. H., et al. (2012). "Immunogold detection of L-glutamate and D-serine in 
small synaptic-like microvesicles in adult hippocampal astrocytes." Cerebral Cortex 
(New York, N.Y.: 1991) 22(7): 1690-1697. 
 
Besson, M. J., et al. (1969). "RELEASE OF NEWLY SYNTHESIZED DOPAMINE 
FROM DOPAMINE-CONTAINING TERMINALS IN THE STRIATUM OF THE 
RAT*." Proceedings of the National Academy of Sciences of the United States of 
America 62(3): 741-748. 
 
Beuming, T., et al. (2008). "The binding sites for cocaine and dopamine in the dopamine 
transporter overlap." Nature neuroscience 11(7): 780-789. 
 
Bezzi, P., et al. (2004). "Astrocytes contain a vesicular compartment that is competent for 
regulated exocytosis of glutamate." Nature Neuroscience 7(6): 613-620. 
 
Bindocci, E., et al. (2017). "Three-dimensional Ca2+ imaging advances understanding of 
astrocyte biology." Science 356(6339). 
 
72 
 
 
Bogdanski, D. F. and B. B. Brodie (1969). "The effects of inorganic ions on the storage 
and uptake of H3-norepinephrine by rat heart slices." The Journal of Pharmacology and 
Experimental Therapeutics 165(2): 181-189. 
  
Boison, D., et al. (2010). "Adenosine Signalling and Function in Glial Cells." Cell death 
and differentiation 17(7): 1071-1082. 
 
Boitier, E., et al. (1999). "Mitochondria exert a negative feedback on the propagation of 
intracellular Ca2+ waves in rat cortical astrocytes." The Journal of Cell Biology 145(4): 
795-808. 
 
Bolshakova, A. V., et al. (2016). "Sigma-1 receptor as a potential pharmacological target 
for the treatment of neuropathology." St. Petersburg Polytechnical University Journal: 
Physics and Mathematics 2(1): 31-40. 
 
Bowers, M. S. and P. W. Kalivas (2003). "Forebrain astroglial plasticity is induced 
following withdrawal from repeated cocaine administration." The European Journal of 
Neuroscience 17(6): 1273-1278. 
 
Brecht, M.-L. and D. Herbeck (2014). "Time to relapse following treatment for 
methamphetamine use: a long-term perspective on patterns and predictors." Drug and 
alcohol dependence 139: 18-25. 
 
Bridges, R. J., et al. (2012). "System xc- cystine/glutamate antiporter: an update on 
molecular pharmacology and roles within the CNS." British Journal of Pharmacology 
165(1): 20-34. 
 
Broening, H. W., et al. (1997). "Methamphetamine selectively damages dopaminergic 
innervation to the nucleus accumbens core while sparing the shell." Synapse (New York, 
N.Y.) 27(2): 153-160. 
 
Brune, S., et al. (2013). "Structure of the σ1 receptor and its ligand binding site." Journal 
of Medicinal Chemistry 56(24): 9809-9819. 
 
Carmignoto, G., et al. (1998). "On the Role of Voltage-Dependent Calcium Channels in 
Calcium Signaling of Astrocytes In Situ." The Journal of Neuroscience 18(12): 4637-
4645. 
 
Chai, H., et al. (2017). "Neural circuit-specialized astrocytes: transcriptomic, proteomic, 
morphological and functional evidence." Neuron 95(3): 531-549.e539. 
 
Cheli, V. T., et al. (2016). "L-type voltage-operated calcium channels contribute to 
astrocyte activation in vitro." Glia 64(8): 1396-1415. 
 
 
73 
 
Chu, U. B. and A. E. Ruoho (2016). "Biochemical Pharmacology of the Sigma-1 
Receptor." Molecular Pharmacology 89(1): 142-153. 
 
Covey, D. P., et al. (2013). "Amphetamine elicits opposing actions on readily releasable 
and reserve pools for dopamine." PLoS ONE 8(5): e60763. 
 
Ding, F., et al. (2013). "α1-adrenergic receptors mediate coordinated Ca2+ signaling of 
cortical astrocytes in awake, behaving mice." Cell calcium 54(6). 
 
Duan, S., et al. (2003). "P2X7 Receptor-Mediated Release of Excitatory Amino Acids 
from Astrocytes." The Journal of Neuroscience 23(4): 1320-1328. 
 
Duchen, M. R. (2000). "Mitochondria and calcium: from cell signalling to cell death." 
The Journal of Physiology 529(Pt 1): 57-68. 
 
Dunkley, P. R., et al. (2004). "Tyrosine hydroxylase phosphorylation: regulation and 
consequences." Journal of Neurochemistry 91(5): 1025-1043. 
 
Egashira, T., et al. (1987). "Effects of d-methamphetamine on monkey brain monoamine 
oxidase, in vivo and in vitro." Japanese Journal of Pharmacology 45(1): 79-88. 
 
Entrena, J. M., et al. (2016). "Sigma-1 Receptor Agonism Promotes Mechanical 
Allodynia After Priming the Nociceptive System with Capsaicin." Scientific Reports 
6(1): 37835. 
 
Fellin, T., et al. (2004). "Neuronal Synchrony Mediated by Astrocytic Glutamate through 
Activation of Extrasynaptic NMDA Receptors." Neuron 43(5): 729-743. 
  
Fiacco, T. A. and K. D. McCarthy (2018). "Multiple Lines of Evidence Indicate That 
Gliotransmission Does Not Occur under Physiological Conditions." Journal of 
Neuroscience 38(1): 3-13. 
 
Fischer, J. F. and A. K. Cho (1979). "Chemical release of dopamine from striatal 
homogenates: evidence for an exchange diffusion model." The Journal of Pharmacology 
and Experimental Therapeutics 208(2): 203-209. 
  
Fischer-Smith, K. D., et al. (2012). "Differential effects of cocaine access and withdrawal 
on glutamate type 1 transporter expression in rat nucleus accumbens core and shell." 
Neuroscience 210: 333-339. 
 
Floor, E. and L. Meng (1996). "Amphetamine releases dopamine from synaptic vesicles 
by dual mechanisms." Neuroscience Letters 215(1): 53-56. 
 
Fontanilla, D., et al. (2009). "The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an 
Endogenous Sigma-1 Receptor Regulator." Science (New York, N.Y.) 323(5916): 934-
937. 
 
74 
 
 
Francardo, V., et al. (2014). "Pharmacological stimulation of sigma-1 receptors has 
neurorestorative effects in experimental parkinsonism." Brain: A Journal of Neurology 
137(Pt 7): 1998-2014. 
 
Fraser, R., et al. (2014). "An N-Terminal Threonine Mutation Produces an Efflux-
Favorable, Sodium-Primed Conformation of the Human Dopamine Transporter." 
Molecular Pharmacology 86(1): 76-85. 
 
Freyberg, Z., et al. (2016). "Mechanisms of amphetamine action illuminated through 
optical monitoring of dopamine synaptic vesicles in Drosophila brain." Nature 
Communications 7. 
 
Fu, Y., et al. (2010). "Sigma-1 receptors amplify dopamine D1 receptor signaling at 
presynaptic sites in the prelimbic cortex." Biochimica Et Biophysica Acta 1803(12): 
1396-1408. 
 
Fujita, T., et al. (2014). "Neuronal Transgene Expression in Dominant-Negative SNARE 
Mice." The Journal of Neuroscience 34(50): 16594-16604. 
 
Fung, Y. K. and N. J. Uretsky (1982). "The importance of calcium in the amphetamine-
induced stimulation of dopamine synthesis in mouse striata in vivo." Journal of 
Pharmacology and Experimental Therapeutics 223(2): 477-482. 
  
Gallagher, C. J. and M. W. Salter (2003). "Differential Properties of Astrocyte Calcium 
Waves Mediated by P2Y1 and P2Y2 Receptors." Journal of Neuroscience 23(17): 6728-
6739. 
 
Galloway, A., et al. (2018). "Dopamine Triggers CTCF-Dependent Morphological and 
Genomic Remodeling of Astrocytes." The Journal of Neuroscience: The Official Journal 
of the Society for Neuroscience 38(21): 4846-4858. 
 
Gnegy, M. E., et al. (2004). "Intracellular Ca2+ regulates amphetamine-induced 
dopamine efflux and currents mediated by the human dopamine transporter." Molecular 
Pharmacology 66(1): 137-143. 
 
Gromek, K. A., et al. (2014). "The Oligomeric States of the Purified Sigma-1 Receptor 
Are Stabilized by Ligands." The Journal of Biological Chemistry 289(29): 20333-20344. 
 
Hanner, M., et al. (1996). "Purification, molecular cloning, and expression of the 
mammalian sigma1-binding site." Proceedings of the National Academy of Sciences of 
the United States of America 93(15): 8072-8077. 
 
Hardingham, G. E. and H. Bading (2010). "Synaptic versus extrasynaptic NMDA 
receptor signalling: implications for neurodegenerative disorders." Nature reviews. 
Neuroscience 11(10): 682-696. 
 
75 
 
 
Hasbi, A., et al. (2010). "Heteromerization of dopamine D2 receptors with dopamine D1 
or D5 receptors generates intracellular calcium signaling by different mechanisms." 
Current opinion in pharmacology 10(1): 93. 
 
Hayashi, T. (2019). "The Sigma-1 Receptor in Cellular Stress Signaling." Frontiers in 
Neuroscience 13. 
 
Hayashi, T., et al. (2000). "Ca(2+) signaling via sigma(1)-receptors: novel regulatory 
mechanism affecting intracellular Ca(2+) concentration." The Journal of Pharmacology 
and Experimental Therapeutics 293(3): 788-798. 
 
Hayashi, T. and T.-P. Su (2001). "Regulating ankyrin dynamics: Roles of sigma-1 
receptors." Proceedings of the National Academy of Sciences 98(2): 491-496. 
 
Hayashi, T. and T.-P. Su (2003). "σ-1 Receptors (σ1 Binding Sites) Form Raft-Like 
Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in 
Endoplasmic Reticulum Lipid Compartmentalization and Export." Journal of 
Pharmacology and Experimental Therapeutics 306(2): 718-725. 
 
Hayashi, T. and T.-P. Su (2007). "Sigma-1 receptor chaperones at the ER-mitochondrion 
interface regulate Ca(2+) signaling and cell survival." Cell 131(3): 596-610. 
 
Hedges, D. M., et al. (2018). "Methamphetamine Induces Dopamine Release in the 
Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway." 
Neuropsychopharmacology: Official Publication of the American College of 
Neuropsychopharmacology 43(6): 1405-1414. 
 
Hellewell, S. B. and W. D. Bowen (1990). "A sigma-like binding site in rat 
pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower 
molecular weight suggest a different sigma receptor form from that of guinea pig brain." 
Brain Research 527(2): 244-253. 
 
Hertz, L., et al. (1999). "Astrocytes: Glutamate producers for neurons." Journal of 
Neuroscience Research 57(4): 417-428. 
 
Hiranita, T. and Z. Freyberg (2016). "Importance of Substrate-Coupled Proton Antiport 
by the Vesicular Monoamine Transporter in the Actions of Amphetamines in Drosophila 
Brain." Journal of alcoholism and drug dependence 4(6). 
  
Hol, E. M., et al. (2003). "Neuronal expression of GFAP in patients with Alzheimer 
pathology and identification of novel GFAP splice forms." Molecular Psychiatry 8(9): 
786-796. 
 
 
76 
 
Hong, W. C., et al. (2017). "The sigma-1 receptor modulates dopamine transporter 
conformation and cocaine binding and may thereby potentiate cocaine self-administration 
in rats." The Journal of Biological Chemistry 292(27): 11250-11261. 
 
Hu, G., et al. (2013). "New Fluorescent Substrate Enables Quantitative and High-
Throughput Examination of Vesicular Monoamine Transporter 2 (VMAT2)." ACS 
Chemical Biology 8(9): 1947-1954. 
 
Johnson, L. A. A., et al. (2005). "Regulation of Amphetamine-stimulated Dopamine 
Efflux by Protein Kinase C β." Journal of Biological Chemistry 280(12): 10914-10919. 
 
Jones, C. M., et al. (2020). "Resurgent Methamphetamine Use at Treatment Admission in 
the United States, 2008–2017." American Journal of Public Health 110(4): 509-516. 
 
Kahlig, K. M., et al. (2005). "Amphetamine induces dopamine efflux through a dopamine 
transporter channel." Proceedings of the National Academy of Sciences of the United 
States of America 102(9): 3495-3500. 
 
Khan, M. T., et al. (2019). "Astrocytic rather than neuronal P2X7 receptors modulate the 
function of the tri-synaptic network in the rodent hippocampus." Brain Research Bulletin 
151: 164-173. 
 
Khoshbouei, H., et al. (2003). "Amphetamine-induced dopamine efflux. A voltage-
sensitive and intracellular Na+-dependent mechanism." The Journal of Biological 
Chemistry 278(14): 12070-12077. 
 
Kim, F. J., et al. (2010). "Sigma 1 receptor modulation of G-protein-coupled receptor 
signaling: potentiation of opioid transduction independent from receptor binding." 
Molecular Pharmacology 77(4): 695-703. 
 
Kofuji, P. and E. A. Newman (2004). "POTASSIUM BUFFERING IN THE CENTRAL 
NERVOUS SYSTEM." Neuroscience 129(4): 1045-1056. 
 
Kovács, A. and B. Pál (2017). "Astrocyte-Dependent Slow Inward Currents (SICs) 
Participate in Neuromodulatory Mechanisms in the Pedunculopontine Nucleus (PPN)." 
Frontiers in Cellular Neuroscience 11. 
 
Kuczenski, R. (1975). "Effects of catecholamine releasing agents on synaptosomal 
dopamine biosynthesis: Multiple pools of dopamine or multiple forms of tyrosine 
hydroxylase?" Neuropharmacology 14(1): 1-10. 
 
Lee, M., et al. (2010). "Development of pH Responsive Fluorescent False 
Neurotransmitters." Journal of the American Chemical Society 132(26): 8828-8830. 
 
 
77 
 
Liang, N. Y. and C. O. Rutledge (1982). "Comparison of the release of [3H]dopamine 
from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine." 
Biochemical Pharmacology 31(6): 983-992. 
 
Liddelow, S. A. and B. A. Barres (2017). "Reactive Astrocytes: Production, Function, 
and Therapeutic Potential." Immunity 46(6): 957-967. 
 
Liu, J., et al. (2009). "Activation of phosphatidylinositol-linked novel D1 dopamine 
receptor contributes to the calcium mobilization in cultured rat prefrontal cortical 
astrocytes." Cellular and Molecular Neurobiology 29(3): 317-328. 
 
Liu, J.-F. and J.-X. Li (2018). "TAAR1 in Addiction: Looking Beyond the Tip of the 
Iceberg." Frontiers in Pharmacology 9. 
 
Loland, C. J., et al. (2008). "Relationship between Conformational Changes in the 
Dopamine Transporter and Cocaine-Like Subjective Effects of Uptake Inhibitors." 
Molecular Pharmacology 73(3): 813-823. 
 
Mack, F. and H. Bönisch (1979). "Dissociation constants and lipophilicity of 
catecholamines and related compounds." Naunyn-Schmiedeberg's Archives of 
Pharmacology 310(1): 1-9. 
  
Mager, S., et al. (1994). "Conducting states of a mammalian serotonin transporter." 
Neuron 12(4): 845-859. 
 
Mantle, T. J., et al. (1976). "Inhibition of monoamine oxidase by amphetamine and 
related compounds." Biochemical Pharmacology 25(18): 2073-2077. 
 
Mariotti, L., et al. (2016). "The inhibitory neurotransmitter GABA evokes long-lasting 
Ca(2+) oscillations in cortical astrocytes." Glia 64(3): 363-373. 
 
Martin, W. R., et al. (1976). "The effects of morphine- and nalorphine- like drugs in the 
nondependent and morphine-dependent chronic spinal dog." The Journal of 
Pharmacology and Experimental Therapeutics 197(3): 517-532. 
 
Matsumoto, R. R., et al. (2002). "Involvement of sigma receptors in the behavioral effects 
of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides." 
Neuropharmacology 42(8): 1043-1055. 
 
Matsumoto, R. R. and B. Pouw (2000). "Correlation between neuroleptic binding to σ1 
and σ2 receptors and acute dystonic reactions." European Journal of Pharmacology 
401(2): 155-160. 
 
Mavlyutov, T. A. and A. E. Ruoho (2007). "Ligand-dependent localization and 
intracellular stability of sigma-1 receptors in CHO-K1 cells." Journal of Molecular 
Signaling 2: 8. 
 
78 
 
 
Melikian, H. E. and K. M. Buckley (1999). "Membrane trafficking regulates the activity 
of the human dopamine transporter." The Journal of Neuroscience: The Official Journal 
of the Society for Neuroscience 19(18): 7699-7710. 
 
Mittelsteadt, T., et al. (2009). "Differential mRNA expression patterns of the 
synaptotagmin gene family in the rodent brain." The Journal of Comparative Neurology 
512(4): 514-528. 
 
Moebius, F. F., et al. (1997). "High affinity of sigma 1-binding sites for sterol 
isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol 
C8-C7 isomerase." British Journal of Pharmacology 121(1): 1-6. 
 
Mori, T., et al. (2013). "Sigma-1 Receptor Chaperone at the ER-Mitochondrion Interface 
Mediates the Mitochondrion-ER-Nucleus Signaling for Cellular Survival." PLoS ONE 
8(10). 
 
Moye, S. L., et al. (2019). "Visualizing Astrocyte Morphology Using Lucifer Yellow 
Iontophoresis." JoVE (Journal of Visualized Experiments)(151): e60225. 
 
Mundorf, M. L., et al. (1999). "Amine weak bases disrupt vesicular storage and promote 
exocytosis in chromaffin cells." Journal of Neurochemistry 73(6): 2397-2405. 
 
Nakagawa, T., et al. (2011). "Repeated Exposure to Methamphetamine, Cocaine or 
Morphine Induces Augmentation of Dopamine Release in Rat Mesocorticolimbic Slice 
Co-Cultures." PLoS ONE 6(9). 
 
Narita, M., et al. (2005). "Long-lasting change in brain dynamics induced by 
methamphetamine: enhancement of protein kinase C-dependent astrocytic response and 
behavioral sensitization." Journal of Neurochemistry 93(6): 1383-1392.  
 
Navarrete, M. and A. Araque (2008). "Endocannabinoids mediate neuron-astrocyte 
communication." Neuron 57(6): 883-893. 
 
Navarro, G., et al. (2010). "Direct involvement of sigma-1 receptors in the dopamine D1 
receptor-mediated effects of cocaine." Proceedings of the National Academy of Sciences 
of the United States of America 107(43): 18676-18681. 
 
Navarro, G., et al. (2013). "Cocaine Inhibits Dopamine D2 Receptor Signaling via 
Sigma-1-D2 Receptor Heteromers." PLoS ONE 8(4): e61245. 
 
Nguyen, E. C., et al. (2005). "Involvement of sigma (sigma) receptors in the acute actions 
of methamphetamine: receptor binding and behavioral studies." Neuropharmacology 
49(5): 638-645. 
 
 
79 
 
Nguyen, L., et al. (2014). "Involvement of sigma-1 receptors in the antidepressant-like 
effects of dextromethorphan." PLoS ONE 9(2): e89985. 
 
Nicosia, N., et al. (2009). The Costs of Methamphetamine Use: A National Estimate. 
Santa Monica, CA, RAND Corporation. 
  
Nielsen, A. K., et al. (2019). "Substrate-induced conformational dynamics of the 
dopamine transporter." Nature Communications 10. 
 
Nizar, K., et al. (2013). "In vivo stimulus-induced vasodilation occurs without IP3 
receptor activation and may precede astrocytic calcium increase." The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience 33(19): 8411-8422. 
 
Novakova, M., et al. (1998). "Highly selective σ receptor ligands elevate inositol 1,4,5-
trisphosphate production in rat cardiac myocytes." European Journal of Pharmacology 
353(2): 315-327. 
 
Ortinski, P. I., et al. (2013). "Extrasynaptic Targeting of NMDA Receptors Following D1 
Dopamine Receptor Activation and Cocaine Self-Administration." The Journal of 
Neuroscience 33(22): 9451-9461. 
 
Pal, A., et al. (2008). "Juxtaposition of the Steroid Binding Domain-like I and II Regions 
Constitutes a Ligand Binding Site in the σ-1 Receptor." Journal of Biological Chemistry 
283(28): 19646-19656. 
 
Pál, B. (2015). "Astrocytic Actions on Extrasynaptic Neuronal Currents." Frontiers in 
Cellular Neuroscience 9. 
 
Panenka, W., et al. (2001). "P2X7-Like Receptor Activation in Astrocytes Increases 
Chemokine Monocyte Chemoattractant Protein-1 Expression via Mitogen-Activated 
Protein Kinase." Journal of Neuroscience 21(18): 7135-7142. 
 
Parnis, J., et al. (2013). "Mitochondrial Exchanger NCLX Plays a Major Role in the 
Intracellular Ca2+ Signaling, Gliotransmission, and Proliferation of Astrocytes." The 
Journal of Neuroscience 33(17): 7206-7219. 
 
Parpura, V. and P. G. Haydon (2000). "Physiological astrocytic calcium levels stimulate 
glutamate release to modulate adjacent neurons." Proceedings of the National Academy 
of Sciences of the United States of America 97(15): 8629-8634. 
 
Parri, H. R. and V. Crunelli (2003). "The role of Ca2+ in the generation of spontaneous 
astrocytic Ca2+ oscillations." Neuroscience 120(4): 979-992. 
 
Parsegian, A. and R. E. See (2014). "Dysregulation of Dopamine and Glutamate Release 
in the Prefrontal Cortex and Nucleus Accumbens Following Methamphetamine Self-
 
80 
 
Administration and During Reinstatement in Rats." Neuropsychopharmacology 39(4): 
811-822. 
 
Peter, D., et al. (1994). "The chromaffin granule and synaptic vesicle amine transporters 
differ in substrate recognition and sensitivity to inhibitors." The Journal of Biological 
Chemistry 269(10): 7231-7237. 
 
Peter, D., et al. (1995). "Differential expression of two vesicular monoamine 
transporters." The Journal of Neuroscience: The Official Journal of the Society for 
Neuroscience 15(9): 6179-6188. 
 
Petravicz, J., et al. (2014). "Astrocyte IP3R2-dependent Ca(2+) signaling is not a major 
modulator of neuronal pathways governing behavior." Frontiers in Behavioral 
Neuroscience 8: 384. 
  
Petrelli, F., et al. (2020). "Dysfunction of homeostatic control of dopamine by astrocytes 
in the developing prefrontal cortex leads to cognitive impairments." Molecular Psychiatry 
25(4): 732-749. 
 
Pifl, C., et al. (1995). "Mechanism of the dopamine-releasing actions of amphetamine and 
cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter." 
Molecular Pharmacology 47(2): 368-373. 
 
Pinton, P., et al. (2008). "Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the 
control of apoptosis." Oncogene 27(50): 6407-6418. 
 
Pothos, E. N., et al. (2002). "Stimulation-dependent regulation of the pH, volume and 
quantal size of bovine and rodent secretory vesicles." The Journal of Physiology 542(Pt 
2): 453-476. 
 
Ransohoff, R. M. (2016). "A polarizing question: do M1 and M2 microglia exist?" 
Nature Neuroscience 19(8): 987-991. 
 
Reichenbach, A., et al. (2010). "Morphology and dynamics of perisynaptic glia." Brain 
Research Reviews 63(1-2): 11-25. 
 
Ritz, M. C., et al. (1987). "Cocaine receptors on dopamine transporters are related to self-
administration of cocaine." Science (New York, N.Y.) 237(4819): 1219-1223. 
 
Rivière, G. J., et al. (2000). "Disposition of Methamphetamine and Its Metabolite 
Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration." 
Journal of Pharmacology and Experimental Therapeutics 292(3): 1042-1047. 
 
Robinson, J. B. (1985). "Stereoselectivity and isoenzyme selectivity of monoamine 
oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl." 
Biochemical Pharmacology 34(23): 4105-4108. 
 
81 
 
 
Rodvelt, K. R., et al. (2011). "The sigma receptor agonist SA4503 both attenuates and 
enhances the effects of methamphetamine." Drug and alcohol dependence 116(1-3): 203-
210. 
 
Romero, L., et al. (2012). "Pharmacological properties of S1RA, a new sigma-1 receptor 
antagonist that inhibits neuropathic pain and activity-induced spinal sensitization." 
British Journal of Pharmacology 166(8): 2289-2306. 
 
Romieu, P., et al. (2002). "Involvement of the Sigma 1 Receptor in Cocaine-induced 
Conditioned Place Preference: Possible Dependence on Dopamine Uptake Blockade." 
Neuropsychopharmacology 26(4): 444-455. 
 
Rose, C. R., et al. (2018). "Astroglial Glutamate Signaling and Uptake in the 
Hippocampus." Frontiers in Molecular Neuroscience 10. 
 
Sambo, D. O., et al. (2017). "The sigma-1 receptor modulates methamphetamine 
dysregulation of dopamine neurotransmission." Nature Communications 8(1): 2228. 
 
Savtchouk, I. and A. Volterra (2018). "Gliotransmission: Beyond Black-and-White." 
Journal of Neuroscience 38(1): 14-25. 
 
Schiweck, J., et al. (2018). "Important Shapeshifter: Mechanisms Allowing Astrocytes to 
Respond to the Changing Nervous System During Development, Injury and Disease." 
Frontiers in Cellular Neuroscience 12. 
 
Schmidt, H. R., et al. (2018). "Structural basis for σ 1 receptor ligand recognition." 
Nature Structural & Molecular Biology 25(10): 981-987. 
 
Schmidt, H. R., et al. (2016). "Crystal structure of the human σ1 receptor." Nature 
532(7600): 527-530. 
 
Schousboe, A. (2003). "Role of Astrocytes in the Maintenance and Modulation of 
Glutamatergic and GABAergic Neurotransmission." Neurochemical Research 28(2): 
347-352. 
 
Schuldiner, S., et al. (1995). "Vesicular neurotransmitter transporters: from bacteria to 
humans." Physiological Reviews 75(2): 369-392. 
  
Scobie, K. N., et al. (2014). "Essential role of poly(ADP-ribosyl)ation in cocaine action." 
Proceedings of the National Academy of Sciences 111(5): 2005-2010. 
 
Scofield, M. D., et al. (2016). "Cocaine self-administration and extinction leads to 
reduced GFAP expression and morphometric features of astrocytes in the nucleus 
accumbens core." Biological psychiatry 80(3): 207-215.  
 
 
82 
 
Scofield Michael, D., et al. (2015). "Gq-DREADD Selectively Initiates Glial Glutamate 
Release and Inhibits Cue-induced Cocaine Seeking." Biological psychiatry 78(7): 441-
451. 
 
Seth, P., et al. (2001). "Expression pattern of the type 1 sigma receptor in the brain and 
identity of critical anionic amino acid residues in the ligand-binding domain of the 
receptor." Biochimica Et Biophysica Acta 1540(1): 59-67. 
 
Sherwood, M. W., et al. (2017). "Astrocytic IP3 Rs: Contribution to Ca2+ signalling and 
hippocampal LTP." Glia 65(3): 502-513. 
 
Shigetomi, E., et al. (2013). "Imaging calcium microdomains within entire astrocyte 
territories and endfeet with GCaMPs expressed using adeno-associated viruses." The 
Journal of General Physiology 141(5): 633-647. 
 
Shigetomi, E., et al. (2011). "TRPA1 channels regulate astrocyte resting calcium and 
inhibitory synapse efficacy through GAT-3." Nature Neuroscience 15(1): 70-80. 
 
Sidiropoulou, K., et al. (2001). "Amphetamine administration does not alter protein levels 
of the GLT-1 and EAAC1 glutamate transporter subtypes in rat midbrain, nucleus 
accumbens, striatum, or prefrontal cortex." Brain Research. Molecular Brain Research 
90(2): 187-192. 
 
Siemsen, B. M., et al. (2019). "Effects of Methamphetamine Self-Administration and 
Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core." 
Neuroscience 406: 528-541. 
 
Simmler, L. D., et al. (2013). "Bupropion, methylphenidate, and 3,4-
methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine 
according to their potencies as dopamine uptake inhibitors: implications for the treatment 
of methamphetamine dependence." BMC Research Notes 6: 220. 
 
Sonders, M. S., et al. (1997). "Multiple ionic conductances of the human dopamine 
transporter: the actions of dopamine and psychostimulants." The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience 17(3): 960-974. 
 
Srinivasan, R., et al. (2015). "Ca(2+) signaling in astrocytes from Ip3r2(-/-) mice in brain 
slices and during startle responses in vivo." Nature Neuroscience 18(5): 708-717. 
 
Srivats, S., et al. (2016). "Sigma1 receptors inhibit store-operated Ca2+ entry by 
attenuating coupling of STIM1 to Orai1." The Journal of Cell Biology 213(1): 65-79. 
 
Stein, W. H. (1967). The Movement of Molecules Across Cell Membranes, Elsevier. 
  
 
83 
 
Su, T. P. (1982). "Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to 
etorphine-inaccessible sites in guinea-pig brain." Journal of Pharmacology and 
Experimental Therapeutics 223(2): 284-290. 
 
Su, T. P. and T. Hayashi (2001). "Cocaine affects the dynamics of cytoskeletal proteins 
via sigma(1) receptors." Trends in Pharmacological Sciences 22(9): 456-458. 
 
Su, T. P., et al. (1988). "Steroid binding at sigma receptors suggests a link between 
endocrine, nervous, and immune systems." Science (New York, N.Y.) 240(4849): 219-
221. 
 
Suadicani, S. O., et al. (2006). "P2X7 Receptors Mediate ATP Release and Amplification 
of Astrocytic Intercellular Ca2+ Signaling." The Journal of Neuroscience 26(5): 1378-
1385. 
 
Sulzer, D. (2011). "How Addictive Drugs Disrupt Presynaptic Dopamine 
Neurotransmission." Neuron 69(4): 628-649. 
 
Sulzer, D., et al. (1995). "Amphetamine redistributes dopamine from synaptic vesicles to 
the cytosol and promotes reverse transport." The Journal of Neuroscience: The Official 
Journal of the Society for Neuroscience 15(5 Pt 2): 4102-4108. 
  
Sun, W., et al. (2013). "Glutamate-Dependent Neuroglial Calcium Signaling Differs 
Between Young and Adult Brain." Science (New York, N.Y.) 339(6116): 197-200. 
 
Suzuki, O., et al. (1980). "Inhibition of monoamine oxidase by d-methamphetamine." 
Biochemical Pharmacology 29(14): 2071-2073. 
  
Szumlinski, K. K., et al. (2017). "Methamphetamine Addiction Vulnerability: The 
Glutamate, the Bad, and the Ugly." Biological Psychiatry 81(11): 959-970. 
 
Tainter, M. L. and D. K. Chang (1927). "The Antagonism of the Pressor Action of 
Tyramine by Cocaine." Journal of Pharmacology and Experimental Therapeutics 30(3): 
193-207. 
  
Takahashi, S., et al. (2000). "Involvement of sigma 1 receptors in methamphetamine-
induced behavioral sensitization in rats." Neuroscience Letters 289(1): 21-24. 
 
Takeuchi, A., et al. (2015). "The destiny of Ca2+ released by mitochondria." The Journal 
of Physiological Sciences 65: 11-24. 
 
Tanaka, T., et al. (1991). "Ca2(+)-dependent regulation of the spectrin/actin interaction 
by calmodulin and protein 4.1." The Journal of Biological Chemistry 266(2): 1134-1140. 
 
Testen, A., et al. (2020). "High-Resolution Three-Dimensional Imaging of Individual 
Astrocytes Using Confocal Microscopy." Current Protocols in Neuroscience 91(1): e92. 
 
84 
 
 
Testen, A., et al. (2018). "Region-Specific Reductions in Morphometric Properties and 
Synaptic Colocalization of Astrocytes Following Cocaine Self-Administration and 
Extinction." Frontiers in Cellular Neuroscience 12. 
 
Tong, X., et al. (2012). "Genetically Encoded Calcium Indicators and Astrocyte Calcium 
Microdomains." The Neuroscientist. 
 
Tsai, S.-Y., et al. (2009). "Sigma-1 receptors regulate hippocampal dendritic spine 
formation via a free radical-sensitive mechanism involving Rac1xGTP pathway." 
Proceedings of the National Academy of Sciences of the United States of America 
106(52): 22468-22473. 
 
Underhill, S. M., et al. (2019). "Amphetamines signal through intracellular TAAR1 
receptors coupled to Gα 13 and Gα S in discrete subcellular domains." Molecular 
Psychiatry: 1-16. 
 
Verkhratsky, A. and C. Steinhäuser (2000). "Ion channels in glial cells." Brain Research 
Reviews 32(2): 380-412. 
Verkhratsky, A. and M. Nedergaard (2018). "Physiology of Astroglia." Physiological 
Reviews 98(1): 239-389. 
 
Wang, H. Y., et al. (1995). "Evidence for the coupling of Gq protein to D1-like dopamine 
sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation." 
Molecular Pharmacology 48(6): 988-994. 
 
Wang, K. H., et al. (2015). "Neurotransmitter and psychostimulant recognition by the 
dopamine transporter." Nature 521(7552): 322-327. 
 
Wolfes, A. C., et al. (2017). "A novel method for culturing stellate astrocytes reveals 
spatially distinct Ca2+ signaling and vesicle recycling in astrocytic processes." The 
Journal of General Physiology 149(1): 149-170. 
 
Xie, Z. and G. M. Miller (2007). "Trace amine-associated receptor 1 is a modulator of the 
dopamine transporter." The Journal of Pharmacology and Experimental Therapeutics 
321(1): 128-136. 
 
Xie, Z. and G. M. Miller (2009). "A Receptor Mechanism for Methamphetamine Action 
in Dopamine Transporter Regulation in Brain." The Journal of Pharmacology and 
Experimental Therapeutics 330(1): 316-325. 
 
Yamamoto, H., et al. (1999). "Amino acid residues in the transmembrane domain of the 
type 1 sigma receptor critical for ligand binding." FEBS letters 445(1): 19-22. 
 
 
 
85 
 
Yasui, Y. and T.-P. Su (2016). "Potential Molecular Mechanisms on the Role of the 
Sigma-1 Receptor in the Action of Cocaine and Methamphetamine." Journal of drug and 
alcohol research 5. 
 
Zaczek, R., et al. (1991). "Interactions of [3H]amphetamine with rat brain synaptosomes. 
II. Active transport." The Journal of Pharmacology and Experimental Therapeutics 
257(2): 830-835. 
 
Zhang, K., et al. (2017). "Sigma-1 Receptor Plays a Negative Modulation on N-type 
Calcium Channel." Frontiers in Pharmacology 8. 
 
Zhang, X., et al. (2018). "Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-
Iodothyronamine, But Not by Tyramine or β-Phenylethylamine." Frontiers in 
Pharmacology 9. 
 
Zhang, Y., et al. (2001). "Comparison of cocaine- and methamphetamine-evoked 
dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat 
brain during acute, chronic, and early withdrawal conditions." Annals of the New York 
Academy of Sciences 937: 93-120. 
 
Zhang, Y., et al. (2015). "Involvement of sigma-1 receptor in astrocyte activation induced 
by methamphetamine via up-regulation of its own expression." Journal of 
Neuroinflammation 12: 29. 
  
Zonta, M., et al. (2003). "Neuron-to-astrocyte signaling is central to the dynamic control 
of brain microcirculation." Nature Neuroscience 6(1): 43-50. 
 
 
 
 
86 
 
VITA 
 
RICHIK NEOGI 
EDUCATION 
Bachelor of Science in Neuroscience from Washington State University Vancouver 
ACADEMIC EMPLOYMENT 
Research Assistant to Dr. Summer Gibbs, Department of Biomedical Engineering, 
Oregon Health Sciences University. Summer 2013-Summer 2014 
Research Assistant to Dr. Michael Morgan, Department of Neuroscience, 
Washington State University Vancouver, Winter 2018-Summer 2018 
PRESENTATIONS AT PROFESSIONAL MEETINGS 
Neogi, R and Morgan, M.M., “Microglial P2X4 Receptors Contribute to Morphine 
Tolerance Mediated by the Periaqueductal Gray” at the International Narcotics 
Research Conference, July 2019, New York, NY 
ACADEMIC AWARDS 
 Recipient of funding from WSU Alcohol and Drug Research Program 
